[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f0bQSS8E40QqP0V19jHVOABZsy8QeXLWO4vLc8Tb0vKQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":37,"phaseBuckets":84,"rows":91},"Akeso",[4,6],"Akesobio Australia Pty Ltd",157,false,83,34,31607,89,2,[15,18,20,23,26,29,32,34],{"name":16,"count":17},"Hepatocellular Carcinoma",8,{"name":19,"count":17},"Atopic Dermatitis",{"name":21,"count":22},"Advanced Solid Tumors",7,{"name":24,"count":25},"Advanced Malignant Tumors",6,{"name":27,"count":28},"Psoriasis",5,{"name":30,"count":31},"Solid Tumor",4,{"name":33,"count":31},"Nasopharyngeal Carcinoma",{"name":35,"count":36},"Pancreatic Cancer",3,[38,43,48,53,58,63,68,72,76,80],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05184712","Phase 3 Clinical Study of AK112 for NSCLC Patients","2023-03-10","Ivonescimab (SMT112 or AK112)",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05319431","A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC","2023-08-15","AK104",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05499390","AK112 in Advanced Non-Small Cell Lung Cancer","2024-01-29","AK112",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05960955","Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","2024-11-30","Cadonilimab",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05840016","AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","2025-02-28","AK112, Carboplatin, Paxlitaxel",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06641388","A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects","2025-04-30","Ebronucimab",{"nctId":69,"briefTitle":70,"date":71,"intervention":47},"NCT05859750","A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","2025-06",{"nctId":73,"briefTitle":74,"date":75,"intervention":47},"NCT05215067","A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer","2025-06-30",{"nctId":77,"briefTitle":78,"date":75,"intervention":79},"NCT06756126","A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)","AK120",{"nctId":81,"briefTitle":82,"date":83,"intervention":47},"NCT05990127","A Study of AK104\u002FTislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS \u003C 1% Non-small Cell Lung Cancer","2025-08-05",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,445,762,864,958,1028,1074,1123,1161,1204,1238,1275,1305,1343,1369,1391,1413,1440,1458,1476,1498,1516,1534,1560,1578,1603,1621,1639,1663,1681,1699,1717,1735,1846,1884,1914,1953,1989,2025,2051,2096,2131,2183,2209,2231,2295,2327,2357,2379,2401,2428,2450,2473,2500,2518,2536,2554,2578,2596,2614,2632,2650,2668,2686,2704,2722,2740,2758,2776,2794,2812,2830,2848,2866,2884,2908,2926,2944,2975,3044,3068,3093,3116,3139,3157,3175,3200,3222,3244,3268,3336,3418,3461,3485,3503,3521,3555,3577,3602,3627,3645,3663,3681,3699,3723,3741,3759,3777,3802,3820,3845,3863,3881,3912,3930,3948,3966,3984,4002,4020,4038,4056,4081,4106,4124,4149,4174,4201,4219,4237],{"intervention":52,"totalTrials":93,"cells":94},29,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":136,"PHASE3":398,"PHASE4":441,"NA":443},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":135,"soonestReadout":128},[100,111,123],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"NCT04047290","A Study of AK112, a PD-1\u002FVEGF Bispecific Antibody, for Advanced Solid Tumors","COMPLETED",[86],"2024-02-27","2019-09-20",80,[109],"Neoplasms Malignant",[52],{"nctId":112,"briefTitle":113,"status":103,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT05116007","Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC",[86],"2023-12-04","2021-03-29",35,[119],"SCLC, Extensive Stage",[52,121,122],"Etoposide","Carboplatin",{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"NCT07340476","A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects","ACTIVE_NOT_RECRUITING",[86],"2026-04-10","2026-07-30","2025-12-11",108,[133],"Healthy Male Subjects",[52,52],1,{"trials":137,"activeCount":397,"soonestReadout":214},[138,147,161,171,184,196,210,221,233,245,257,268,280,295,309,318,331,341,350,363,373,385],{"nctId":139,"briefTitle":140,"status":103,"phases":141,"primaryCompletion":66,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":146},"NCT05432492","A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)",[87],"2025-06-14","2022-08-03",40,[16],[52],{"nctId":148,"briefTitle":149,"status":103,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":160},"NCT04870177","Study of AK112 in the Treatment of Advanced Gynecological Tumors",[87],"2024-05-10","2021-04-09",53,[155,156,157,158,159],"Gynecologic Cancer","Cancer Metastatic","Ovarian Neoplasms","Cervical Neoplasm","Endometrial Neoplasms",[52],{"nctId":162,"briefTitle":163,"status":103,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":131,"conditions":168,"interventions":170},"NCT04900363","A Trial of AK112 (PD-1\u002FVEGF Bispecific Antibody) in Patients With NSCLC",[86,87],"2024-06-28","2025-12-09","2021-05-21",[169],"Non-small Cell Lung Cancer",[52],{"nctId":172,"briefTitle":173,"status":174,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT07052253","A Phase II Clinical Study of AK104\u002FAK112 in Combination With TT-00420 Tablet for Advanced HCC.","RECRUITING",[87],"2027-05-10","2027-12-31","2025-07-18",100,[181],"Hepatocellular Carcinoma (HCC)",[183,47,52],"TT-00420",{"nctId":185,"briefTitle":186,"status":174,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT05689853","Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors",[86,87],"2026-12","2027-06","2023-04-14",87,[193],"Solid Tumor, Adult",[195,52],"AK119",{"nctId":197,"briefTitle":198,"status":126,"phases":199,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":205},"NCT05229497","A Phase Ib\u002FII Study of AK112 in Combination With AK117 in Advanced Malignant Tumors",[86,87],"2026-12-31","2027-06-30","2022-05-04",154,[24],[52,206,122,207,208,209],"AK117","Cisplatin","5-Fluorouracil","Gemcitabine",{"nctId":211,"briefTitle":212,"status":126,"phases":213,"primaryCompletion":214,"completion":200,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT05247684","AK112 Neoadjuvant\u002FAdjuvant Treatment for Resectable NSCLC",[87],"2025-08-18","2022-02-20",90,[218],"Resectable Non-small Cell Lung Cancer",[52,122,207,220],"Paclitaxel",{"nctId":222,"briefTitle":223,"status":224,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},"NCT07158840","AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment","NOT_YET_RECRUITING",[87],"2028-09","2029-06","2025-09-05",60,[231],"Non-Small Cell Lung Cancer",[52],{"nctId":234,"briefTitle":235,"status":174,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":243},"NCT06560112","An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer",[87],"2026-05-01","2027-05-01","2024-11-12",172,[242],"Recurrent Ovarian Cancer",[47,52,244],"Chemotherapy",{"nctId":246,"briefTitle":247,"status":224,"phases":248,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":255},"NCT07357220","A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases",[86,87],"2027-02-28","2028-02-28","2026-03-02",72,[254],"Colorectal Cancer With Hepatic Metastases",[256,52],"VG2025",{"nctId":258,"briefTitle":259,"status":174,"phases":260,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":266},"NCT07114315","A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer",[87],"2027-08","2028-08","2025-09-19",160,[35],[52,267],"AK130",{"nctId":269,"briefTitle":270,"status":174,"phases":271,"primaryCompletion":272,"completion":226,"start":273,"enrollment":274,"conditions":275,"interventions":276},"NCT06530251","A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)",[86,87],"2026-06","2024-09-24",280,[16],[52,57,277,267,278,279],"AK127","Sintilimab","Bevacizumab biosimilar",{"nctId":281,"briefTitle":282,"status":126,"phases":283,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":290},"NCT05846867","A Phase Ib\u002FII Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR\u002FMSS Colorectal Cancer",[86,87],"2026-05-08","2026-08-11","2023-05-08",170,[289],"Colorectal Cancer",[195,52,291,292,293,294],"Oxaliplatin","Irinotecan","Calcium folinate","Fluorouracil",{"nctId":296,"briefTitle":297,"status":126,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT05382442","A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer",[87],"2026-05-15","2028-08-12","2022-06-27",254,[304],"Metastatic Colorectal Cancer",[52,206,291,306,292,307,308],"Capecitabine","Leucovorin","5-fluorouracil",{"nctId":310,"briefTitle":311,"status":103,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":203,"conditions":316,"interventions":317},"NCT05214482","A Study of AK112 in Advanced Malignant Tumors",[86,87],"2025-11-20","2025-12-31","2022-01-22",[24],[52,206,244],{"nctId":319,"briefTitle":320,"status":321,"phases":322,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":329},"NCT05636267","Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients","TERMINATED",[86,87],"2025-02-24","2025-04-15","2023-02-10",59,[328],"NSCLC",[195,52,330,122],"Pemetrexed",{"nctId":332,"briefTitle":333,"status":126,"phases":334,"primaryCompletion":335,"completion":188,"start":336,"enrollment":337,"conditions":338,"interventions":339},"NCT04736823","A Trial of AK112 (PD1\u002FVEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC",[87],"2026-07","2021-02-01",265,[328],[52,330,220,122,340],"Docetaxel",{"nctId":342,"briefTitle":343,"status":103,"phases":344,"primaryCompletion":345,"completion":346,"start":347,"enrollment":326,"conditions":348,"interventions":349},"NCT04597541","A Study of AK112 for Advanced Solid Tumors",[86,87],"2022-03-31","2024-07-15","2020-10-21",[193],[52],{"nctId":351,"briefTitle":352,"status":126,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT05904379","AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer",[86,87],"2026-06-30","2027-01-31","2023-07-13",233,[359],"Advanced Non-small-cell Lung Cancer",[52,47,122,361,362,340],"paclitaxel","pemetrexed",{"nctId":364,"briefTitle":365,"status":174,"phases":366,"primaryCompletion":367,"completion":368,"start":66,"enrollment":369,"conditions":370,"interventions":372},"NCT06938321","A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer",[86,87],"2027-05","2027-12",135,[371],"Biliary Tract Cancer",[52,267],{"nctId":374,"briefTitle":375,"status":126,"phases":376,"primaryCompletion":377,"completion":201,"start":378,"enrollment":379,"conditions":380,"interventions":383},"NCT05227664","A Study of AK117\u002FAK112 in Metastatic Triple-Negative Breast Cancer",[87],"2026-12-30","2022-03-23",120,[381,382],"Metastatic Triple-negative Breast Cancer","Locally Advanced Triple-negative Breast Cancer",[206,52,384,361],"Nab paclitaxel",{"nctId":386,"briefTitle":387,"status":224,"phases":388,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":395},"NCT07591090","A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer",[87],"2027-09-01","2029-02-04","2026-06-01",200,[394],"Advanced Breast Cancer",[396,52],"AK146D1 for",16,{"trials":399,"activeCount":31,"soonestReadout":51},[400,407,420,430],{"nctId":49,"briefTitle":50,"status":126,"phases":401,"primaryCompletion":51,"completion":200,"start":402,"enrollment":403,"conditions":404,"interventions":405},[88],"2022-11-09",398,[359],[52,406],"Pembrolizumab",{"nctId":408,"briefTitle":409,"status":174,"phases":410,"primaryCompletion":411,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":417},"NCT06951503","AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer",[88],"2027-01-13","2029-01-07","2025-05-27",560,[416],"Colorectal Adenocarcinoma",[52,291,292,418,419],"Leucovorin and 5-FU","Bevacizumab",{"nctId":421,"briefTitle":422,"status":174,"phases":423,"primaryCompletion":424,"completion":425,"start":426,"enrollment":414,"conditions":427,"interventions":429},"NCT07010263","A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy",[88],"2028-12-31","2029-07-31","2025-06-13",[428],"Small Cell Lung Cancer",[52],{"nctId":431,"briefTitle":432,"status":174,"phases":433,"primaryCompletion":188,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":439},"NCT06767527","AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced\u002F Metastatic Triple-negative Breast Cancer",[88],"2028-12","2025-02-07",416,[438],"Triple-Negative Breast Cancer (TNBC)",[52,440],"Nab-paclitaxel",{"trials":442,"activeCount":97},[],{"trials":444,"activeCount":97},[],{"intervention":47,"totalTrials":446,"cells":447},32,{"EARLY_PHASE1":448,"PHASE1":461,"PHASE2":492,"PHASE3":684,"PHASE4":758,"NA":760},{"trials":449,"activeCount":97},[450],{"nctId":451,"briefTitle":452,"status":103,"phases":453,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":460},"NCT05021120","A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours",[85],"2024-10-01","2025-04-01","2021-10-12",67,[459],"Advanced or Metastatic Solid Tumours",[277,47],{"trials":462,"activeCount":135,"soonestReadout":478},[463,474,483],{"nctId":464,"briefTitle":465,"status":103,"phases":466,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":471,"interventions":473},"NCT04572152","A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors",[86],"2023-05-02","2023-08-31","2020-12-07",23,[472],"Advanced or Metastatic Solid Tumors",[195,47],{"nctId":475,"briefTitle":476,"status":224,"phases":477,"primaryCompletion":478,"completion":377,"start":391,"enrollment":479,"conditions":480,"interventions":482},"NCT07619001","A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations",[86],"2026-09-30",158,[481],"Healthy Male Adults Participants",[47,47],{"nctId":484,"briefTitle":485,"status":103,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":179,"conditions":490,"interventions":491},"NCT05559554","A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects",[86],"2023-03-24","2023-04-06","2022-10-25",[133],[47,47],{"trials":493,"activeCount":683,"soonestReadout":46},[494,506,513,522,526,530,539,548,559,570,580,589,597,604,615,626,637,649,653,665,673],{"nctId":495,"briefTitle":496,"status":103,"phases":497,"primaryCompletion":498,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":505},"NCT04380805","A Study of AK104, a PD-1\u002FCTLA-4 Bispecific Antibody in Subjects With Recurrent\u002FMetastatic Cervical Cancer",[87],"2022-12-22","2023-01-31","2020-07-15",30,[503,504],"Recurrent Cervical Cancer","Metastatic Cervical Cancer",[47],{"nctId":44,"briefTitle":45,"status":126,"phases":507,"primaryCompletion":46,"completion":75,"start":508,"enrollment":229,"conditions":509,"interventions":511},[87],"2022-06-28",[510],"Unresectable, Non-metastatic Hepatocellular Carcinoma",[47,512],"Lenvatinib",{"nctId":514,"briefTitle":515,"status":103,"phases":516,"primaryCompletion":517,"completion":517,"start":325,"enrollment":518,"conditions":519,"interventions":521},"NCT05227651","AK104 in Neoadjuvant Treatment of Cervical Cancer",[87],"2024-09-27",14,[520],"Cervical Cancer",[47],{"nctId":172,"briefTitle":173,"status":174,"phases":523,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":524,"interventions":525},[87],[181],[183,47,52],{"nctId":234,"briefTitle":235,"status":174,"phases":527,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":528,"interventions":529},[87],[242],[47,52,244],{"nctId":531,"briefTitle":532,"status":321,"phases":533,"primaryCompletion":534,"completion":534,"start":535,"enrollment":25,"conditions":536,"interventions":538},"NCT04547101","A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H\u002FdMMR Solid Tumors",[87],"2022-09-30","2020-04-24",[537],"MSI-H\u002FdMMR Solid Tumor",[47],{"nctId":540,"briefTitle":541,"status":321,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":547},"NCT05559541","Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors",[86,87],"2024-05-31","2022-12-15",33,[193],[195,47],{"nctId":549,"briefTitle":550,"status":103,"phases":551,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":558},"NCT04172454","Safety and Efficacy of AK104, a PD-1\u002FCTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors",[86,87],"2021-06-17","2022-09-23","2019-12-20",68,[21,557],"Melanoma",[47],{"nctId":560,"briefTitle":561,"status":174,"phases":562,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":568},"NCT05932212","AK104 for Recurrent or Metastatic Vulvar Cancer",[87],"2025-12-15","2023-08-25",20,[567],"Vulvar Cancer",[47,569],"AK104+ Paclitaxel+Cisplatin or Carboplatin",{"nctId":69,"briefTitle":70,"status":174,"phases":571,"primaryCompletion":71,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":576},[87],"2025-12","2023-05-25",78,[35],[47,47,209,577,578,579],"Nab-Paclitaxel","Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil\u002FCalcium folinate","Oxaliplatin + Irinotecan + 5-Fluorouracil\u002FLeucovorin",{"nctId":581,"briefTitle":582,"status":103,"phases":583,"primaryCompletion":584,"completion":585,"start":586,"enrollment":10,"conditions":587,"interventions":588},"NCT04220307","A Study of a PD-1\u002FCTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma",[87],"2021-05-15","2023-03-09","2020-04-26",[33],[47],{"nctId":590,"briefTitle":591,"status":321,"phases":592,"primaryCompletion":534,"completion":534,"start":593,"enrollment":25,"conditions":594,"interventions":596},"NCT04444141","A Study of PD-1\u002FCTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma",[86,87],"2020-05-15",[595],"Peripheral T-cell Lymphoma",[47],{"nctId":73,"briefTitle":74,"status":126,"phases":598,"primaryCompletion":75,"completion":354,"start":599,"enrollment":600,"conditions":601,"interventions":603},[87],"2022-03-09",44,[602],"Advanced Non-small Cell Lung Cancer",[47,340],{"nctId":605,"briefTitle":606,"status":103,"phases":607,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":614},"NCT03852251","A Study of AK104, a PD-1\u002FCTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX\u002FXELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma",[86,87],"2024-03-25","2019-01-18",338,[612,21,613],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[47,291,306],{"nctId":616,"briefTitle":617,"status":174,"phases":618,"primaryCompletion":619,"completion":355,"start":620,"enrollment":621,"conditions":622,"interventions":624},"NCT04982276","A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma",[86,87],"2025-12-30","2021-08-23",138,[623],"Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma",[625,361,361,47],"AK109",{"nctId":627,"briefTitle":628,"status":103,"phases":629,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":635},"NCT04868708","A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer",[87],"2024-02-28","2021-04-01",50,[634],"Recurrent or Metastatic Cervical Cancer",[47,419,220,636],"Cisplatin or Carboplatin",{"nctId":638,"briefTitle":639,"status":640,"phases":641,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":646,"interventions":647},"NCT05235542","A Phase Ib\u002FII Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors","UNKNOWN",[86,87],"2023-03","2024-03","2022-07-12",130,[24],[47,206,306,291,207,220,292,340,648],"5-FU",{"nctId":351,"briefTitle":352,"status":126,"phases":650,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":651,"interventions":652},[86,87],[359],[52,47,122,361,362,340],{"nctId":654,"briefTitle":655,"status":126,"phases":656,"primaryCompletion":314,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":663},"NCT05256472","A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced\u002FMetastatic Renal Cell Carcinoma",[87],"2026-06-22","2023-07-06",70,[661,662],"Renal Cell Carcinoma","First-line Treatment",[47,664],"axitinib",{"nctId":666,"briefTitle":667,"status":103,"phases":668,"primaryCompletion":669,"completion":669,"start":670,"enrollment":326,"conditions":671,"interventions":672},"NCT04444167","A Study of Anti-PD-1\u002FCTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma",[86,87],"2023-11-20","2020-07-07",[16],[47,512],{"nctId":674,"briefTitle":675,"status":103,"phases":676,"primaryCompletion":677,"completion":678,"start":679,"enrollment":446,"conditions":680,"interventions":681},"NCT04728321","A Study of Anti-PD-1\u002FCTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma",[87],"2022-08-02","2023-08-02","2021-01-27",[16],[682,47],"AK104 lenvatinib",9,{"trials":685,"activeCount":25,"soonestReadout":83},[686,697,707,717,728,737,747],{"nctId":687,"briefTitle":688,"status":224,"phases":689,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":696},"NCT07449780","A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma",[88],"2027-11-17","2028-02-15","2026-03-31",422,[695],"Gastric \u002F Gastroesophageal Junction Adenocarcinoma",[47,47,306,291],{"nctId":698,"briefTitle":699,"status":103,"phases":700,"primaryCompletion":701,"completion":702,"start":703,"enrollment":704,"conditions":705,"interventions":706},"NCT05008783","A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G\u002FGEJ Adenocarcinoma",[88],"2024-12-06","2025-08-01","2021-09-17",610,[612,613],[47],{"nctId":708,"briefTitle":709,"status":174,"phases":710,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":716},"NCT05489289","A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection",[88],"2026-01-28","2027-01-01","2023-01-05",570,[16],[47],{"nctId":718,"briefTitle":719,"status":126,"phases":720,"primaryCompletion":619,"completion":619,"start":721,"enrollment":722,"conditions":723,"interventions":724},"NCT04982237","A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer",[88],"2021-08-27",445,[520],[47,361,725,726,727],"carboplatin","cisplatin","bevacizumab",{"nctId":81,"briefTitle":82,"status":224,"phases":729,"primaryCompletion":83,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":735},[88],"2026-11-28","2023-11-14",642,[734],"Locally Advanced or Metastatic NSCLC",[47,736,725,330,220],"Tislelizumab",{"nctId":738,"briefTitle":739,"status":174,"phases":740,"primaryCompletion":741,"completion":742,"start":743,"enrollment":744,"conditions":745,"interventions":746},"NCT06371157","A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable\u002FNon-metastatic Hepatocellular Carcinoma",[88],"2025-10-25","2026-05-23","2024-08-02",469,[16],[47,512],{"nctId":748,"briefTitle":749,"status":126,"phases":750,"primaryCompletion":751,"completion":752,"start":753,"enrollment":754,"conditions":755,"interventions":757},"NCT05235516","A Study of AK104\u002FPlacebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer",[88],"2026-05","2029-05","2022-06-21",636,[756],"Locally Advanced Cervical Carcinoma",[47,726],{"trials":759,"activeCount":97},[],{"trials":761,"activeCount":97},[],{"intervention":220,"totalTrials":763,"cells":764},13,{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":769,"PHASE3":824,"PHASE4":860,"NA":862},{"trials":766,"activeCount":97},[],{"trials":768,"activeCount":97},[],{"trials":770,"activeCount":22,"soonestReadout":214},[771,775,790,800,804,808,812,816,820],{"nctId":211,"briefTitle":212,"status":126,"phases":772,"primaryCompletion":214,"completion":200,"start":215,"enrollment":216,"conditions":773,"interventions":774},[87],[218],[52,122,207,220],{"nctId":776,"briefTitle":777,"status":174,"phases":778,"primaryCompletion":188,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":785},"NCT06943820","AK129 Combination Therapy for Advanced Solid Tumors",[86,87],"2028-05","2025-05-21",230,[783,784,416,21],"Non-small Cell Lung Cancer Stage IIIB\u002FIV","Head and Neck Squamous Cell Carcinoma (HNSCC)",[786,330,220,122,786,340,787,648,788,220,340,244,786,789],"AK129","Cis-platinum","Cetuximab","Penpulimab",{"nctId":791,"briefTitle":792,"status":174,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":216,"conditions":797,"interventions":799},"NCT07263919","Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)",[87],"2030-03","2031-12","2025-12-19",[798],"Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma",[57,207,220],{"nctId":616,"briefTitle":617,"status":174,"phases":801,"primaryCompletion":619,"completion":355,"start":620,"enrollment":621,"conditions":802,"interventions":803},[86,87],[623],[625,361,361,47],{"nctId":627,"briefTitle":628,"status":103,"phases":805,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":806,"interventions":807},[87],[634],[47,419,220,636],{"nctId":638,"briefTitle":639,"status":640,"phases":809,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":810,"interventions":811},[86,87],[24],[47,206,306,291,207,220,292,340,648],{"nctId":332,"briefTitle":333,"status":126,"phases":813,"primaryCompletion":335,"completion":188,"start":336,"enrollment":337,"conditions":814,"interventions":815},[87],[328],[52,330,220,122,340],{"nctId":351,"briefTitle":352,"status":126,"phases":817,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":818,"interventions":819},[86,87],[359],[52,47,122,361,362,340],{"nctId":374,"briefTitle":375,"status":126,"phases":821,"primaryCompletion":377,"completion":201,"start":378,"enrollment":379,"conditions":822,"interventions":823},[87],[381,382],[206,52,384,361],{"trials":825,"activeCount":36,"soonestReadout":83},[826,839,843,847],{"nctId":827,"briefTitle":828,"status":174,"phases":829,"primaryCompletion":830,"completion":831,"start":832,"enrollment":833,"conditions":834,"interventions":836},"NCT06341335","A Study of AK104\u002FPlacebo Plus AK109\u002FPlacebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma",[88],"2026-11","2027-07","2024-06-19",506,[835],"Gastric and Gastroesophageal Junction Adenocarcinoma",[837,838,361],"cadonilimab","pulocimab",{"nctId":718,"briefTitle":719,"status":126,"phases":840,"primaryCompletion":619,"completion":619,"start":721,"enrollment":722,"conditions":841,"interventions":842},[88],[520],[47,361,725,726,727],{"nctId":81,"briefTitle":82,"status":224,"phases":844,"primaryCompletion":83,"completion":730,"start":731,"enrollment":732,"conditions":845,"interventions":846},[88],[734],[47,736,725,330,220],{"nctId":848,"briefTitle":849,"status":103,"phases":850,"primaryCompletion":851,"completion":852,"start":853,"enrollment":854,"conditions":855,"interventions":858},"NCT03866993","A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer",[88],"2020-10-08","2022-01-14","2018-12-20",350,[856,857],"Lung Cancer Non-small Cell Stage IV","Squamous Cell Lung Cancer",[859,220,122],"AK105",{"trials":861,"activeCount":97},[],{"trials":863,"activeCount":97},[],{"intervention":57,"totalTrials":683,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":883,"PHASE3":912,"PHASE4":954,"NA":956},{"trials":867,"activeCount":97},[],{"trials":869,"activeCount":135,"soonestReadout":874},[870],{"nctId":871,"briefTitle":872,"status":224,"phases":873,"primaryCompletion":874,"completion":875,"start":876,"enrollment":229,"conditions":877,"interventions":880},"NCT06913218","A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104\u002FAK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC",[86],"2028-02-23","2028-11-06","2025-07-22",[878,879],"Pancreas Cancer","Pancreas Cancer, Duct Cell Adenocarcinoma",[881,57,42,882],"AK154","mFOLFORINOX",{"trials":884,"activeCount":31,"soonestReadout":56},[885,896,900,904],{"nctId":886,"briefTitle":887,"status":174,"phases":888,"primaryCompletion":368,"completion":889,"start":890,"enrollment":891,"conditions":892,"interventions":894},"NCT07245446","A Study of Ivonescimab in First-Line ES-SCLC",[87],"2028-06","2025-10-29",180,[893],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)",[895,57,206,121,122],"Ivonescimab",{"nctId":269,"briefTitle":270,"status":174,"phases":897,"primaryCompletion":272,"completion":226,"start":273,"enrollment":274,"conditions":898,"interventions":899},[86,87],[16],[52,57,277,267,278,279],{"nctId":791,"briefTitle":792,"status":174,"phases":901,"primaryCompletion":794,"completion":795,"start":796,"enrollment":216,"conditions":902,"interventions":903},[87],[798],[57,207,220],{"nctId":54,"briefTitle":55,"status":174,"phases":905,"primaryCompletion":56,"completion":906,"start":907,"enrollment":216,"conditions":908,"interventions":910},[87],"2027-11-30","2023-11-13",[909],"Resectable Gastric or Gastroesophageal Junction Adenocarcinoma",[57,206,291,911,340,208],"Tegafur-gimeracil-oteracil potassium",{"trials":913,"activeCount":31,"soonestReadout":932},[914,928,938,950],{"nctId":915,"briefTitle":916,"status":174,"phases":917,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":925},"NCT07412613","Neoadjuvant\u002FAdjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer",[88],"2030-06-15","2031-03-15","2026-04-15",386,[923,924],"Resectable Colon Cancer","MSI-H\u002FdMMR Colorectal Cancer",[57,291,306,926,927],"5- Fluorouracil","Calcium Folinate",{"nctId":929,"briefTitle":930,"status":174,"phases":931,"primaryCompletion":932,"completion":933,"start":239,"enrollment":414,"conditions":934,"interventions":936},"NCT06617416","A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC",[88],"2026-10-28","2028-12-30",[935],"NSCLC (Non-small Cell Lung Cancer)",[57,937],"Sugemalimab",{"nctId":939,"briefTitle":940,"status":174,"phases":941,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":946,"interventions":948},"NCT07023315","A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G\u002FGEJ Adenocarcinoma",[88],"2029-07","2031-07","2025-08-14",760,[947],"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma",[57,949],"SOX chemotherapy",{"nctId":827,"briefTitle":828,"status":174,"phases":951,"primaryCompletion":830,"completion":831,"start":832,"enrollment":833,"conditions":952,"interventions":953},[88],[835],[837,838,361],{"trials":955,"activeCount":97},[],{"trials":957,"activeCount":97},[],{"intervention":122,"totalTrials":959,"cells":960},12,{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":969,"PHASE3":999,"PHASE4":1024,"NA":1026},{"trials":962,"activeCount":97},[],{"trials":964,"activeCount":97},[965],{"nctId":112,"briefTitle":113,"status":103,"phases":966,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":967,"interventions":968},[86],[119],[52,121,122],{"trials":970,"activeCount":25,"soonestReadout":214},[971,975,979,983,987,991,995],{"nctId":197,"briefTitle":198,"status":126,"phases":972,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":973,"interventions":974},[86,87],[24],[52,206,122,207,208,209],{"nctId":211,"briefTitle":212,"status":126,"phases":976,"primaryCompletion":214,"completion":200,"start":215,"enrollment":216,"conditions":977,"interventions":978},[87],[218],[52,122,207,220],{"nctId":886,"briefTitle":887,"status":174,"phases":980,"primaryCompletion":368,"completion":889,"start":890,"enrollment":891,"conditions":981,"interventions":982},[87],[893],[895,57,206,121,122],{"nctId":776,"briefTitle":777,"status":174,"phases":984,"primaryCompletion":188,"completion":779,"start":780,"enrollment":781,"conditions":985,"interventions":986},[86,87],[783,784,416,21],[786,330,220,122,786,340,787,648,788,220,340,244,786,789],{"nctId":319,"briefTitle":320,"status":321,"phases":988,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":989,"interventions":990},[86,87],[328],[195,52,330,122],{"nctId":332,"briefTitle":333,"status":126,"phases":992,"primaryCompletion":335,"completion":188,"start":336,"enrollment":337,"conditions":993,"interventions":994},[87],[328],[52,330,220,122,340],{"nctId":351,"briefTitle":352,"status":126,"phases":996,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":997,"interventions":998},[86,87],[359],[52,47,122,361,362,340],{"trials":1000,"activeCount":13,"soonestReadout":83},[1001,1005,1009,1020],{"nctId":718,"briefTitle":719,"status":126,"phases":1002,"primaryCompletion":619,"completion":619,"start":721,"enrollment":722,"conditions":1003,"interventions":1004},[88],[520],[47,361,725,726,727],{"nctId":81,"briefTitle":82,"status":224,"phases":1006,"primaryCompletion":83,"completion":730,"start":731,"enrollment":732,"conditions":1007,"interventions":1008},[88],[734],[47,736,725,330,220],{"nctId":1010,"briefTitle":1011,"status":321,"phases":1012,"primaryCompletion":1013,"completion":1014,"start":1015,"enrollment":1016,"conditions":1017,"interventions":1018},"NCT03866980","A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer",[88],"2023-06-30","2023-12-31","2018-11-27",164,[856],[859,725,362,1019],"Anlotinib",{"nctId":848,"briefTitle":849,"status":103,"phases":1021,"primaryCompletion":851,"completion":852,"start":853,"enrollment":854,"conditions":1022,"interventions":1023},[88],[856,857],[859,220,122],{"trials":1025,"activeCount":97},[],{"trials":1027,"activeCount":97},[],{"intervention":291,"totalTrials":17,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1056,"PHASE4":1070,"NA":1072},{"trials":1031,"activeCount":97},[],{"trials":1033,"activeCount":97},[],{"trials":1035,"activeCount":36,"soonestReadout":56},[1036,1040,1044,1048,1052],{"nctId":281,"briefTitle":282,"status":126,"phases":1037,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":1038,"interventions":1039},[86,87],[289],[195,52,291,292,293,294],{"nctId":296,"briefTitle":297,"status":126,"phases":1041,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":1042,"interventions":1043},[87],[304],[52,206,291,306,292,307,308],{"nctId":605,"briefTitle":606,"status":103,"phases":1045,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":1046,"interventions":1047},[86,87],[612,21,613],[47,291,306],{"nctId":54,"briefTitle":55,"status":174,"phases":1049,"primaryCompletion":56,"completion":906,"start":907,"enrollment":216,"conditions":1050,"interventions":1051},[87],[909],[57,206,291,911,340,208],{"nctId":638,"briefTitle":639,"status":640,"phases":1053,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":1054,"interventions":1055},[86,87],[24],[47,206,306,291,207,220,292,340,648],{"trials":1057,"activeCount":36,"soonestReadout":411},[1058,1062,1066],{"nctId":915,"briefTitle":916,"status":174,"phases":1059,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":1060,"interventions":1061},[88],[923,924],[57,291,306,926,927],{"nctId":687,"briefTitle":688,"status":224,"phases":1063,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":1064,"interventions":1065},[88],[695],[47,47,306,291],{"nctId":408,"briefTitle":409,"status":174,"phases":1067,"primaryCompletion":411,"completion":412,"start":413,"enrollment":414,"conditions":1068,"interventions":1069},[88],[416],[52,291,292,418,419],{"trials":1071,"activeCount":97},[],{"trials":1073,"activeCount":97},[],{"intervention":207,"totalTrials":22,"cells":1075},{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1109,"PHASE4":1119,"NA":1121},{"trials":1077,"activeCount":97},[],{"trials":1079,"activeCount":97},[],{"trials":1081,"activeCount":36,"soonestReadout":214},[1082,1086,1090,1094,1105],{"nctId":197,"briefTitle":198,"status":126,"phases":1083,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":1084,"interventions":1085},[86,87],[24],[52,206,122,207,208,209],{"nctId":211,"briefTitle":212,"status":126,"phases":1087,"primaryCompletion":214,"completion":200,"start":215,"enrollment":216,"conditions":1088,"interventions":1089},[87],[218],[52,122,207,220],{"nctId":791,"briefTitle":792,"status":174,"phases":1091,"primaryCompletion":794,"completion":795,"start":796,"enrollment":216,"conditions":1092,"interventions":1093},[87],[798],[57,207,220],{"nctId":1095,"briefTitle":1096,"status":103,"phases":1097,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1103},"NCT04736810","A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma",[87],"2022-06-09","2023-12-18","2021-02-25",28,[33],[859,207,209,1104],"Anlotinib hydrochloride",{"nctId":638,"briefTitle":639,"status":640,"phases":1106,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":1107,"interventions":1108},[86,87],[24],[47,206,306,291,207,220,292,340,648],{"trials":1110,"activeCount":13,"soonestReadout":619},[1111,1115],{"nctId":718,"briefTitle":719,"status":126,"phases":1112,"primaryCompletion":619,"completion":619,"start":721,"enrollment":722,"conditions":1113,"interventions":1114},[88],[520],[47,361,725,726,727],{"nctId":748,"briefTitle":749,"status":126,"phases":1116,"primaryCompletion":751,"completion":752,"start":753,"enrollment":754,"conditions":1117,"interventions":1118},[88],[756],[47,726],{"trials":1120,"activeCount":97},[],{"trials":1122,"activeCount":97},[],{"intervention":330,"totalTrials":25,"cells":1124},{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1147,"PHASE4":1157,"NA":1159},{"trials":1126,"activeCount":97},[],{"trials":1128,"activeCount":97},[],{"trials":1130,"activeCount":36,"soonestReadout":354},[1131,1135,1139,1143],{"nctId":776,"briefTitle":777,"status":174,"phases":1132,"primaryCompletion":188,"completion":779,"start":780,"enrollment":781,"conditions":1133,"interventions":1134},[86,87],[783,784,416,21],[786,330,220,122,786,340,787,648,788,220,340,244,786,789],{"nctId":319,"briefTitle":320,"status":321,"phases":1136,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":1137,"interventions":1138},[86,87],[328],[195,52,330,122],{"nctId":332,"briefTitle":333,"status":126,"phases":1140,"primaryCompletion":335,"completion":188,"start":336,"enrollment":337,"conditions":1141,"interventions":1142},[87],[328],[52,330,220,122,340],{"nctId":351,"briefTitle":352,"status":126,"phases":1144,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":1145,"interventions":1146},[86,87],[359],[52,47,122,361,362,340],{"trials":1148,"activeCount":135,"soonestReadout":83},[1149,1153],{"nctId":81,"briefTitle":82,"status":224,"phases":1150,"primaryCompletion":83,"completion":730,"start":731,"enrollment":732,"conditions":1151,"interventions":1152},[88],[734],[47,736,725,330,220],{"nctId":1010,"briefTitle":1011,"status":321,"phases":1154,"primaryCompletion":1013,"completion":1014,"start":1015,"enrollment":1016,"conditions":1155,"interventions":1156},[88],[856],[859,725,362,1019],{"trials":1158,"activeCount":97},[],{"trials":1160,"activeCount":97},[],{"intervention":42,"totalTrials":31,"cells":1162},{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1171,"PHASE3":1190,"PHASE4":1200,"NA":1202},{"trials":1164,"activeCount":97},[],{"trials":1166,"activeCount":135,"soonestReadout":874},[1167],{"nctId":871,"briefTitle":872,"status":224,"phases":1168,"primaryCompletion":874,"completion":875,"start":876,"enrollment":229,"conditions":1169,"interventions":1170},[86],[878,879],[881,57,42,882],{"trials":1172,"activeCount":13,"soonestReadout":368},[1173,1177],{"nctId":886,"briefTitle":887,"status":174,"phases":1174,"primaryCompletion":368,"completion":889,"start":890,"enrollment":891,"conditions":1175,"interventions":1176},[87],[893],[895,57,206,121,122],{"nctId":1178,"briefTitle":1179,"status":224,"phases":1180,"primaryCompletion":1181,"completion":1182,"start":1183,"enrollment":1184,"conditions":1185,"interventions":1187},"NCT07560124","A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer",[86,87],"2028-06-06","2030-09-14","2026-06-06",286,[1186],"Breast Cancer",[1188,895,1189],"AK138D1","treatment of physician's choice",{"trials":1191,"activeCount":135,"soonestReadout":41},[1192],{"nctId":39,"briefTitle":40,"status":126,"phases":1193,"primaryCompletion":41,"completion":1194,"start":1195,"enrollment":1196,"conditions":1197,"interventions":1199},[88],"2026-09","2022-01-25",322,[1198],"Non-Squamous Non-small Cell Lung Cancer",[42],{"trials":1201,"activeCount":97},[],{"trials":1203,"activeCount":97},[],{"intervention":306,"totalTrials":28,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1224,"PHASE4":1234,"NA":1236},{"trials":1207,"activeCount":97},[],{"trials":1209,"activeCount":97},[],{"trials":1211,"activeCount":135,"soonestReadout":299},[1212,1216,1220],{"nctId":296,"briefTitle":297,"status":126,"phases":1213,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":1214,"interventions":1215},[87],[304],[52,206,291,306,292,307,308],{"nctId":605,"briefTitle":606,"status":103,"phases":1217,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":1218,"interventions":1219},[86,87],[612,21,613],[47,291,306],{"nctId":638,"briefTitle":639,"status":640,"phases":1221,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":1222,"interventions":1223},[86,87],[24],[47,206,306,291,207,220,292,340,648],{"trials":1225,"activeCount":13,"soonestReadout":690},[1226,1230],{"nctId":915,"briefTitle":916,"status":174,"phases":1227,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":1228,"interventions":1229},[88],[923,924],[57,291,306,926,927],{"nctId":687,"briefTitle":688,"status":224,"phases":1231,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":1232,"interventions":1233},[88],[695],[47,47,306,291],{"trials":1235,"activeCount":97},[],{"trials":1237,"activeCount":97},[],{"intervention":512,"totalTrials":31,"cells":1239},{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1265,"PHASE4":1271,"NA":1273},{"trials":1241,"activeCount":97},[],{"trials":1243,"activeCount":97},[],{"trials":1245,"activeCount":13,"soonestReadout":46},[1246,1250,1261],{"nctId":44,"briefTitle":45,"status":126,"phases":1247,"primaryCompletion":46,"completion":75,"start":508,"enrollment":229,"conditions":1248,"interventions":1249},[87],[510],[47,512],{"nctId":1251,"briefTitle":1252,"status":224,"phases":1253,"primaryCompletion":1254,"completion":201,"start":1255,"enrollment":379,"conditions":1256,"interventions":1258},"NCT06984718","A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC",[87],"2026-11-30","2025-06-25",[1257,16],"HCC",[1259,1260],"AK104+lenvatinib","lenvatinib",{"nctId":666,"briefTitle":667,"status":103,"phases":1262,"primaryCompletion":669,"completion":669,"start":670,"enrollment":326,"conditions":1263,"interventions":1264},[86,87],[16],[47,512],{"trials":1266,"activeCount":135,"soonestReadout":741},[1267],{"nctId":738,"briefTitle":739,"status":174,"phases":1268,"primaryCompletion":741,"completion":742,"start":743,"enrollment":744,"conditions":1269,"interventions":1270},[88],[16],[47,512],{"trials":1272,"activeCount":97},[],{"trials":1274,"activeCount":97},[],{"intervention":292,"totalTrials":31,"cells":1276},{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1295,"PHASE4":1301,"NA":1303},{"trials":1278,"activeCount":97},[],{"trials":1280,"activeCount":97},[],{"trials":1282,"activeCount":13,"soonestReadout":284},[1283,1287,1291],{"nctId":281,"briefTitle":282,"status":126,"phases":1284,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":1285,"interventions":1286},[86,87],[289],[195,52,291,292,293,294],{"nctId":296,"briefTitle":297,"status":126,"phases":1288,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":1289,"interventions":1290},[87],[304],[52,206,291,306,292,307,308],{"nctId":638,"briefTitle":639,"status":640,"phases":1292,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":1293,"interventions":1294},[86,87],[24],[47,206,306,291,207,220,292,340,648],{"trials":1296,"activeCount":135,"soonestReadout":411},[1297],{"nctId":408,"briefTitle":409,"status":174,"phases":1298,"primaryCompletion":411,"completion":412,"start":413,"enrollment":414,"conditions":1299,"interventions":1300},[88],[416],[52,291,292,418,419],{"trials":1302,"activeCount":97},[],{"trials":1304,"activeCount":97},[],{"intervention":789,"totalTrials":36,"cells":1306},{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1317,"PHASE4":1339,"NA":1341},{"trials":1308,"activeCount":97},[],{"trials":1310,"activeCount":97},[],{"trials":1312,"activeCount":135,"soonestReadout":188},[1313],{"nctId":776,"briefTitle":777,"status":174,"phases":1314,"primaryCompletion":188,"completion":779,"start":780,"enrollment":781,"conditions":1315,"interventions":1316},[86,87],[783,784,416,21],[786,330,220,122,786,340,787,648,788,220,340,244,786,789],{"trials":1318,"activeCount":135,"soonestReadout":1323},[1319,1329],{"nctId":1320,"briefTitle":1321,"status":126,"phases":1322,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1326,"conditions":1327,"interventions":1328},"NCT04974398","A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma",[88],"2026-02-23","2026-12-23","2021-08-16",296,[33],[789],{"nctId":1330,"briefTitle":1331,"status":640,"phases":1332,"primaryCompletion":619,"completion":1333,"start":1334,"enrollment":229,"conditions":1335,"interventions":1337},"NCT05244642","A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma",[88],"2026-03-30","2022-02-15",[1336],"Hodgkin Disease Lymphoma",[789,1338],"Investigator's choice of Chemotherapy",{"trials":1340,"activeCount":97},[],{"trials":1342,"activeCount":97},[],{"intervention":419,"totalTrials":36,"cells":1344},{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1355,"PHASE4":1365,"NA":1367},{"trials":1346,"activeCount":97},[],{"trials":1348,"activeCount":97},[],{"trials":1350,"activeCount":97},[1351],{"nctId":627,"briefTitle":628,"status":103,"phases":1352,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":1353,"interventions":1354},[87],[634],[47,419,220,636],{"trials":1356,"activeCount":13,"soonestReadout":619},[1357,1361],{"nctId":718,"briefTitle":719,"status":126,"phases":1358,"primaryCompletion":619,"completion":619,"start":721,"enrollment":722,"conditions":1359,"interventions":1360},[88],[520],[47,361,725,726,727],{"nctId":408,"briefTitle":409,"status":174,"phases":1362,"primaryCompletion":411,"completion":412,"start":413,"enrollment":414,"conditions":1363,"interventions":1364},[88],[416],[52,291,292,418,419],{"trials":1366,"activeCount":97},[],{"trials":1368,"activeCount":97},[],{"intervention":927,"totalTrials":13,"cells":1370},{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1381,"PHASE4":1387,"NA":1389},{"trials":1372,"activeCount":97},[],{"trials":1374,"activeCount":97},[],{"trials":1376,"activeCount":135,"soonestReadout":284},[1377],{"nctId":281,"briefTitle":282,"status":126,"phases":1378,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":1379,"interventions":1380},[86,87],[289],[195,52,291,292,293,294],{"trials":1382,"activeCount":135,"soonestReadout":918},[1383],{"nctId":915,"briefTitle":916,"status":174,"phases":1384,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":1385,"interventions":1386},[88],[923,924],[57,291,306,926,927],{"trials":1388,"activeCount":97},[],{"trials":1390,"activeCount":97},[],{"intervention":577,"totalTrials":13,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1403,"PHASE4":1409,"NA":1411},{"trials":1394,"activeCount":97},[],{"trials":1396,"activeCount":97},[],{"trials":1398,"activeCount":135,"soonestReadout":71},[1399],{"nctId":69,"briefTitle":70,"status":174,"phases":1400,"primaryCompletion":71,"completion":572,"start":573,"enrollment":574,"conditions":1401,"interventions":1402},[87],[35],[47,47,209,577,578,579],{"trials":1404,"activeCount":135,"soonestReadout":188},[1405],{"nctId":431,"briefTitle":432,"status":174,"phases":1406,"primaryCompletion":188,"completion":434,"start":435,"enrollment":436,"conditions":1407,"interventions":1408},[88],[438],[52,440],{"trials":1410,"activeCount":97},[],{"trials":1412,"activeCount":97},[],{"intervention":1414,"totalTrials":135,"cells":1415},"Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine",{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1422,"PHASE4":1436,"NA":1438},{"trials":1417,"activeCount":97},[],{"trials":1419,"activeCount":97},[],{"trials":1421,"activeCount":97},[],{"trials":1423,"activeCount":135,"soonestReadout":1428},[1424],{"nctId":1425,"briefTitle":1426,"status":174,"phases":1427,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1433},"NCT06953999","A Phase III Study of Ivonescimab + Chemo With\u002FWithout AK117 in Metastatic Pancreatic Cancer",[88],"2027-05-14","2028-05-14","2025-06-11",999,[35],[1414,1434,1435],"Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine","Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine",{"trials":1437,"activeCount":97},[],{"trials":1439,"activeCount":97},[],{"intervention":1434,"totalTrials":135,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1454,"NA":1456},{"trials":1443,"activeCount":97},[],{"trials":1445,"activeCount":97},[],{"trials":1447,"activeCount":97},[],{"trials":1449,"activeCount":135,"soonestReadout":1428},[1450],{"nctId":1425,"briefTitle":1426,"status":174,"phases":1451,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":1452,"interventions":1453},[88],[35],[1414,1434,1435],{"trials":1455,"activeCount":97},[],{"trials":1457,"activeCount":97},[],{"intervention":1435,"totalTrials":135,"cells":1459},{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1472,"NA":1474},{"trials":1461,"activeCount":97},[],{"trials":1463,"activeCount":97},[],{"trials":1465,"activeCount":97},[],{"trials":1467,"activeCount":135,"soonestReadout":1428},[1468],{"nctId":1425,"briefTitle":1426,"status":174,"phases":1469,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":1470,"interventions":1471},[88],[35],[1414,1434,1435],{"trials":1473,"activeCount":97},[],{"trials":1475,"activeCount":97},[],{"intervention":62,"totalTrials":135,"cells":1477},{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1484,"PHASE4":1494,"NA":1496},{"trials":1479,"activeCount":97},[],{"trials":1481,"activeCount":97},[],{"trials":1483,"activeCount":97},[],{"trials":1485,"activeCount":135,"soonestReadout":61},[1486],{"nctId":59,"briefTitle":60,"status":126,"phases":1487,"primaryCompletion":61,"completion":200,"start":1488,"enrollment":1489,"conditions":1490,"interventions":1492},[88],"2023-08-17",532,[1491],"Advanced Squamous Non Small Cell Lung Cancer",[62,1493],"Tislelizumab, Carboplatin, Paxlitaxel",{"trials":1495,"activeCount":97},[],{"trials":1497,"activeCount":97},[],{"intervention":1493,"totalTrials":135,"cells":1499},{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1512,"NA":1514},{"trials":1501,"activeCount":97},[],{"trials":1503,"activeCount":97},[],{"trials":1505,"activeCount":97},[],{"trials":1507,"activeCount":135,"soonestReadout":61},[1508],{"nctId":59,"briefTitle":60,"status":126,"phases":1509,"primaryCompletion":61,"completion":200,"start":1488,"enrollment":1489,"conditions":1510,"interventions":1511},[88],[1491],[62,1493],{"trials":1513,"activeCount":97},[],{"trials":1515,"activeCount":97},[],{"intervention":406,"totalTrials":135,"cells":1517},{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1522,"PHASE3":1524,"PHASE4":1530,"NA":1532},{"trials":1519,"activeCount":97},[],{"trials":1521,"activeCount":97},[],{"trials":1523,"activeCount":97},[],{"trials":1525,"activeCount":135,"soonestReadout":51},[1526],{"nctId":49,"briefTitle":50,"status":126,"phases":1527,"primaryCompletion":51,"completion":200,"start":402,"enrollment":403,"conditions":1528,"interventions":1529},[88],[359],[52,406],{"trials":1531,"activeCount":97},[],{"trials":1533,"activeCount":97},[],{"intervention":1535,"totalTrials":135,"cells":1536},"AK117 in combination with AK112",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1556,"NA":1558},{"trials":1538,"activeCount":97},[],{"trials":1540,"activeCount":97},[],{"trials":1542,"activeCount":97},[],{"trials":1544,"activeCount":135,"soonestReadout":1549},[1545],{"nctId":1546,"briefTitle":1547,"status":174,"phases":1548,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":1552,"conditions":1553,"interventions":1555},"NCT06601335","A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R\u002FM HNSCC)",[88],"2027-01","2027-10","2024-10-30",510,[1554],"Head and Neck Squamous Cell Carcinoma",[1535],{"trials":1557,"activeCount":97},[],{"trials":1559,"activeCount":97},[],{"intervention":926,"totalTrials":135,"cells":1561},{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1566,"PHASE3":1568,"PHASE4":1574,"NA":1576},{"trials":1563,"activeCount":97},[],{"trials":1565,"activeCount":97},[],{"trials":1567,"activeCount":97},[],{"trials":1569,"activeCount":135,"soonestReadout":918},[1570],{"nctId":915,"briefTitle":916,"status":174,"phases":1571,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":1572,"interventions":1573},[88],[923,924],[57,291,306,926,927],{"trials":1575,"activeCount":97},[],{"trials":1577,"activeCount":97},[],{"intervention":1579,"totalTrials":135,"cells":1580},"AK112, Gemcitabine, Cisplatin",{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1587,"PHASE4":1599,"NA":1601},{"trials":1582,"activeCount":97},[],{"trials":1584,"activeCount":97},[],{"trials":1586,"activeCount":97},[],{"trials":1588,"activeCount":135,"soonestReadout":1593},[1589],{"nctId":1590,"briefTitle":1591,"status":126,"phases":1592,"primaryCompletion":1593,"completion":368,"start":1594,"enrollment":1595,"conditions":1596,"interventions":1597},"NCT06591520","AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer",[88],"2026-10","2024-10-20",682,[371],[1579,1598],"Durvalumab, Gemcitabine, Cisplatin",{"trials":1600,"activeCount":97},[],{"trials":1602,"activeCount":97},[],{"intervention":1598,"totalTrials":135,"cells":1604},{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1611,"PHASE4":1617,"NA":1619},{"trials":1606,"activeCount":97},[],{"trials":1608,"activeCount":97},[],{"trials":1610,"activeCount":97},[],{"trials":1612,"activeCount":135,"soonestReadout":1593},[1613],{"nctId":1590,"briefTitle":1591,"status":126,"phases":1614,"primaryCompletion":1593,"completion":368,"start":1594,"enrollment":1595,"conditions":1615,"interventions":1616},[88],[371],[1579,1598],{"trials":1618,"activeCount":97},[],{"trials":1620,"activeCount":97},[],{"intervention":937,"totalTrials":135,"cells":1622},{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1627,"PHASE3":1629,"PHASE4":1635,"NA":1637},{"trials":1624,"activeCount":97},[],{"trials":1626,"activeCount":97},[],{"trials":1628,"activeCount":97},[],{"trials":1630,"activeCount":135,"soonestReadout":932},[1631],{"nctId":929,"briefTitle":930,"status":174,"phases":1632,"primaryCompletion":932,"completion":933,"start":239,"enrollment":414,"conditions":1633,"interventions":1634},[88],[935],[57,937],{"trials":1636,"activeCount":97},[],{"trials":1638,"activeCount":97},[],{"intervention":1640,"totalTrials":135,"cells":1641},"Ivonescimab, docetaxel",{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1646,"PHASE3":1648,"PHASE4":1659,"NA":1661},{"trials":1643,"activeCount":97},[],{"trials":1645,"activeCount":97},[],{"trials":1647,"activeCount":97},[],{"trials":1649,"activeCount":135,"soonestReadout":367},[1650],{"nctId":1651,"briefTitle":1652,"status":174,"phases":1653,"primaryCompletion":367,"completion":1654,"start":1655,"enrollment":1656,"conditions":1657,"interventions":1658},"NCT06928389","Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer",[88],"2030-06","2025-07-08",536,[231],[1640],{"trials":1660,"activeCount":97},[],{"trials":1662,"activeCount":97},[],{"intervention":949,"totalTrials":135,"cells":1664},{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1669,"PHASE3":1671,"PHASE4":1677,"NA":1679},{"trials":1666,"activeCount":97},[],{"trials":1668,"activeCount":97},[],{"trials":1670,"activeCount":97},[],{"trials":1672,"activeCount":135,"soonestReadout":942},[1673],{"nctId":939,"briefTitle":940,"status":174,"phases":1674,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":1675,"interventions":1676},[88],[947],[57,949],{"trials":1678,"activeCount":97},[],{"trials":1680,"activeCount":97},[],{"intervention":838,"totalTrials":135,"cells":1682},{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1689,"PHASE4":1695,"NA":1697},{"trials":1684,"activeCount":97},[],{"trials":1686,"activeCount":97},[],{"trials":1688,"activeCount":97},[],{"trials":1690,"activeCount":135,"soonestReadout":830},[1691],{"nctId":827,"briefTitle":828,"status":174,"phases":1692,"primaryCompletion":830,"completion":831,"start":832,"enrollment":833,"conditions":1693,"interventions":1694},[88],[835],[837,838,361],{"trials":1696,"activeCount":97},[],{"trials":1698,"activeCount":97},[],{"intervention":418,"totalTrials":135,"cells":1700},{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1713,"NA":1715},{"trials":1702,"activeCount":97},[],{"trials":1704,"activeCount":97},[],{"trials":1706,"activeCount":97},[],{"trials":1708,"activeCount":135,"soonestReadout":411},[1709],{"nctId":408,"briefTitle":409,"status":174,"phases":1710,"primaryCompletion":411,"completion":412,"start":413,"enrollment":414,"conditions":1711,"interventions":1712},[88],[416],[52,291,292,418,419],{"trials":1714,"activeCount":97},[],{"trials":1716,"activeCount":97},[],{"intervention":736,"totalTrials":135,"cells":1718},{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1723,"PHASE3":1725,"PHASE4":1731,"NA":1733},{"trials":1720,"activeCount":97},[],{"trials":1722,"activeCount":97},[],{"trials":1724,"activeCount":97},[],{"trials":1726,"activeCount":135,"soonestReadout":83},[1727],{"nctId":81,"briefTitle":82,"status":224,"phases":1728,"primaryCompletion":83,"completion":730,"start":731,"enrollment":732,"conditions":1729,"interventions":1730},[88],[734],[47,736,725,330,220],{"trials":1732,"activeCount":97},[],{"trials":1734,"activeCount":97},[],{"intervention":206,"totalTrials":518,"cells":1736},{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1760,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1738,"activeCount":97},[],{"trials":1740,"activeCount":97},[1741,1750],{"nctId":1742,"briefTitle":1743,"status":103,"phases":1744,"primaryCompletion":1195,"completion":1745,"start":1746,"enrollment":1747,"conditions":1748,"interventions":1749},"NCT04728334","A Phase 1 Dose Escalation and Expansion Study of AK117",[86],"2023-05-12","2021-03-23",49,[109],[206],{"nctId":1751,"briefTitle":1752,"status":103,"phases":1753,"primaryCompletion":1754,"completion":1754,"start":1755,"enrollment":1756,"conditions":1757,"interventions":1758},"NCT04349969","A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104",[86],"2022-11-08","2020-04-23",38,[109],[206,1759],"AK117+AK104",{"trials":1761,"activeCount":1839,"soonestReadout":56},[1762,1772,1776,1786,1790,1799,1803,1807,1816,1820,1824,1835],{"nctId":1763,"briefTitle":1764,"status":174,"phases":1765,"primaryCompletion":1766,"completion":1767,"start":1768,"enrollment":274,"conditions":1769,"interventions":1771},"NCT06642792","A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma",[86,87],"2027-11","2028-02","2025-01-17",[1770],"Classic Hodgkin Lymphoma",[786,206],{"nctId":197,"briefTitle":198,"status":126,"phases":1773,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":1774,"interventions":1775},[86,87],[24],[52,206,122,207,208,209],{"nctId":1777,"briefTitle":1778,"status":126,"phases":1779,"primaryCompletion":1780,"completion":572,"start":1781,"enrollment":555,"conditions":1782,"interventions":1784},"NCT04980885","A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia",[86,87],"2025-09","2021-08-13",[1783],"Acute Myeloid Leukemia",[206,1785],"Azacitidine",{"nctId":886,"briefTitle":887,"status":174,"phases":1787,"primaryCompletion":368,"completion":889,"start":890,"enrollment":891,"conditions":1788,"interventions":1789},[87],[893],[895,57,206,121,122],{"nctId":1791,"briefTitle":1792,"status":174,"phases":1793,"primaryCompletion":1794,"completion":272,"start":1795,"enrollment":216,"conditions":1796,"interventions":1798},"NCT06196203","A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes",[87],"2026-01","2024-02-07",[1797],"Higher-risk Myelodysplastic Syndromes",[206,1785],{"nctId":296,"briefTitle":297,"status":126,"phases":1800,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":1801,"interventions":1802},[87],[304],[52,206,291,306,292,307,308],{"nctId":310,"briefTitle":311,"status":103,"phases":1804,"primaryCompletion":313,"completion":314,"start":315,"enrollment":203,"conditions":1805,"interventions":1806},[86,87],[24],[52,206,244],{"nctId":1808,"briefTitle":1809,"status":126,"phases":1810,"primaryCompletion":1780,"completion":572,"start":1811,"enrollment":1812,"conditions":1813,"interventions":1815},"NCT04900350","A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome",[86,87],"2021-06-18",136,[1814],"Myelodysplastic Syndrome",[206,1785],{"nctId":54,"briefTitle":55,"status":174,"phases":1817,"primaryCompletion":56,"completion":906,"start":907,"enrollment":216,"conditions":1818,"interventions":1819},[87],[909],[57,206,291,911,340,208],{"nctId":638,"briefTitle":639,"status":640,"phases":1821,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":1822,"interventions":1823},[86,87],[24],[47,206,306,291,207,220,292,340,648],{"nctId":1825,"briefTitle":1826,"status":224,"phases":1827,"primaryCompletion":1828,"completion":1829,"start":1830,"enrollment":891,"conditions":1831,"interventions":1833},"NCT06387420","A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia",[86,87],"2026-04","2027-04","2024-04-29",[1832],"ACUTE MYELOID LEUKEMIA; AML",[206,1785,1834],"Venetoclax",{"nctId":374,"briefTitle":375,"status":126,"phases":1836,"primaryCompletion":377,"completion":201,"start":378,"enrollment":379,"conditions":1837,"interventions":1838},[87],[381,382],[206,52,384,361],10,{"trials":1841,"activeCount":97},[],{"trials":1843,"activeCount":97},[],{"trials":1845,"activeCount":97},[],{"intervention":340,"totalTrials":25,"cells":1847},{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1878,"PHASE4":1880,"NA":1882},{"trials":1849,"activeCount":97},[],{"trials":1851,"activeCount":97},[],{"trials":1853,"activeCount":28,"soonestReadout":56},[1854,1858,1862,1866,1870,1874],{"nctId":776,"briefTitle":777,"status":174,"phases":1855,"primaryCompletion":188,"completion":779,"start":780,"enrollment":781,"conditions":1856,"interventions":1857},[86,87],[783,784,416,21],[786,330,220,122,786,340,787,648,788,220,340,244,786,789],{"nctId":73,"briefTitle":74,"status":126,"phases":1859,"primaryCompletion":75,"completion":354,"start":599,"enrollment":600,"conditions":1860,"interventions":1861},[87],[602],[47,340],{"nctId":54,"briefTitle":55,"status":174,"phases":1863,"primaryCompletion":56,"completion":906,"start":907,"enrollment":216,"conditions":1864,"interventions":1865},[87],[909],[57,206,291,911,340,208],{"nctId":638,"briefTitle":639,"status":640,"phases":1867,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":1868,"interventions":1869},[86,87],[24],[47,206,306,291,207,220,292,340,648],{"nctId":332,"briefTitle":333,"status":126,"phases":1871,"primaryCompletion":335,"completion":188,"start":336,"enrollment":337,"conditions":1872,"interventions":1873},[87],[328],[52,330,220,122,340],{"nctId":351,"briefTitle":352,"status":126,"phases":1875,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":1876,"interventions":1877},[86,87],[359],[52,47,122,361,362,340],{"trials":1879,"activeCount":97},[],{"trials":1881,"activeCount":97},[],{"trials":1883,"activeCount":97},[],{"intervention":1785,"totalTrials":31,"cells":1885},{"EARLY_PHASE1":1886,"PHASE1":1888,"PHASE2":1890,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1887,"activeCount":97},[],{"trials":1889,"activeCount":97},[],{"trials":1891,"activeCount":31,"soonestReadout":1780},[1892,1896,1900,1904],{"nctId":1777,"briefTitle":1778,"status":126,"phases":1893,"primaryCompletion":1780,"completion":572,"start":1781,"enrollment":555,"conditions":1894,"interventions":1895},[86,87],[1783],[206,1785],{"nctId":1791,"briefTitle":1792,"status":174,"phases":1897,"primaryCompletion":1794,"completion":272,"start":1795,"enrollment":216,"conditions":1898,"interventions":1899},[87],[1797],[206,1785],{"nctId":1808,"briefTitle":1809,"status":126,"phases":1901,"primaryCompletion":1780,"completion":572,"start":1811,"enrollment":1812,"conditions":1902,"interventions":1903},[86,87],[1814],[206,1785],{"nctId":1825,"briefTitle":1826,"status":224,"phases":1905,"primaryCompletion":1828,"completion":1829,"start":1830,"enrollment":891,"conditions":1906,"interventions":1907},[86,87],[1832],[206,1785,1834],{"trials":1909,"activeCount":97},[],{"trials":1911,"activeCount":97},[],{"trials":1913,"activeCount":97},[],{"intervention":244,"totalTrials":31,"cells":1915},{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1947,"PHASE4":1949,"NA":1951},{"trials":1917,"activeCount":97},[],{"trials":1919,"activeCount":97},[],{"trials":1921,"activeCount":36,"soonestReadout":237},[1922,1926,1939,1943],{"nctId":234,"briefTitle":235,"status":174,"phases":1923,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":1924,"interventions":1925},[87],[242],[47,52,244],{"nctId":1927,"briefTitle":1928,"status":174,"phases":1929,"primaryCompletion":1550,"completion":1930,"start":1931,"enrollment":1932,"conditions":1933,"interventions":1935},"NCT06686030","Combination Therapy of AK112 With Chemotherapy and\u002For Olaparib in Platinum-sensitive Ovarian Cancer",[87],"2028-07","2025-02-17",150,[1934],"Platinum-sensitive Ovarian Cancer",[1936,244,1937,1938],"AK112 low dose","Olaparib","AK112 high dose",{"nctId":776,"briefTitle":777,"status":174,"phases":1940,"primaryCompletion":188,"completion":779,"start":780,"enrollment":781,"conditions":1941,"interventions":1942},[86,87],[783,784,416,21],[786,330,220,122,786,340,787,648,788,220,340,244,786,789],{"nctId":310,"briefTitle":311,"status":103,"phases":1944,"primaryCompletion":313,"completion":314,"start":315,"enrollment":203,"conditions":1945,"interventions":1946},[86,87],[24],[52,206,244],{"trials":1948,"activeCount":97},[],{"trials":1950,"activeCount":97},[],{"trials":1952,"activeCount":97},[],{"intervention":267,"totalTrials":31,"cells":1954},{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1969,"PHASE3":1983,"PHASE4":1985,"NA":1987},{"trials":1956,"activeCount":97},[],{"trials":1958,"activeCount":97},[1959],{"nctId":1960,"briefTitle":1961,"status":103,"phases":1962,"primaryCompletion":1963,"completion":1964,"start":1965,"enrollment":1966,"conditions":1967,"interventions":1968},"NCT05653284","A Study of AK130 in Patients With Advanced Malignant Tumors",[86],"2023-12-12","2024-05-30","2023-02-09",19,[24],[267],{"trials":1970,"activeCount":36,"soonestReadout":272},[1971,1975,1979],{"nctId":258,"briefTitle":259,"status":174,"phases":1972,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":1973,"interventions":1974},[87],[35],[52,267],{"nctId":269,"briefTitle":270,"status":174,"phases":1976,"primaryCompletion":272,"completion":226,"start":273,"enrollment":274,"conditions":1977,"interventions":1978},[86,87],[16],[52,57,277,267,278,279],{"nctId":364,"briefTitle":365,"status":174,"phases":1980,"primaryCompletion":367,"completion":368,"start":66,"enrollment":369,"conditions":1981,"interventions":1982},[86,87],[371],[52,267],{"trials":1984,"activeCount":97},[],{"trials":1986,"activeCount":97},[],{"trials":1988,"activeCount":97},[],{"intervention":1188,"totalTrials":36,"cells":1990},{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":2013,"PHASE3":2019,"PHASE4":2021,"NA":2023},{"trials":1992,"activeCount":97},[],{"trials":1994,"activeCount":13,"soonestReadout":2008},[1995,2004],{"nctId":1996,"briefTitle":1997,"status":174,"phases":1998,"primaryCompletion":1999,"completion":2000,"start":323,"enrollment":179,"conditions":2001,"interventions":2003},"NCT06730386","A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors",[86],"2028-02-26","2028-08-30",[2002],"Solid Cancer",[1188],{"nctId":2005,"briefTitle":2006,"status":174,"phases":2007,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":392,"conditions":2011,"interventions":2012},"NCT07281326","A Study of AK138D1 in Advanced Malignant Tumors",[86],"2026-10-22","2028-05-30","2025-10-22",[2002],[1188],{"trials":2014,"activeCount":135,"soonestReadout":1181},[2015],{"nctId":1178,"briefTitle":1179,"status":224,"phases":2016,"primaryCompletion":1181,"completion":1182,"start":1183,"enrollment":1184,"conditions":2017,"interventions":2018},[86,87],[1186],[1188,895,1189],{"trials":2020,"activeCount":97},[],{"trials":2022,"activeCount":97},[],{"trials":2024,"activeCount":97},[],{"intervention":208,"totalTrials":36,"cells":2026},{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2045,"PHASE4":2047,"NA":2049},{"trials":2028,"activeCount":97},[],{"trials":2030,"activeCount":97},[],{"trials":2032,"activeCount":36,"soonestReadout":56},[2033,2037,2041],{"nctId":197,"briefTitle":198,"status":126,"phases":2034,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":2035,"interventions":2036},[86,87],[24],[52,206,122,207,208,209],{"nctId":296,"briefTitle":297,"status":126,"phases":2038,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":2039,"interventions":2040},[87],[304],[52,206,291,306,292,307,308],{"nctId":54,"briefTitle":55,"status":174,"phases":2042,"primaryCompletion":56,"completion":906,"start":907,"enrollment":216,"conditions":2043,"interventions":2044},[87],[909],[57,206,291,911,340,208],{"trials":2046,"activeCount":97},[],{"trials":2048,"activeCount":97},[],{"trials":2050,"activeCount":97},[],{"intervention":2052,"totalTrials":36,"cells":2053},"AK139",{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2058,"PHASE3":2090,"PHASE4":2092,"NA":2094},{"trials":2055,"activeCount":97},[],{"trials":2057,"activeCount":97},[],{"trials":2059,"activeCount":36,"soonestReadout":478},[2060,2069,2079],{"nctId":2061,"briefTitle":2062,"status":224,"phases":2063,"primaryCompletion":478,"completion":2064,"start":251,"enrollment":2065,"conditions":2066,"interventions":2068},"NCT07436234","A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis",[87],"2027-05-13",111,[2067],"Seasonal Allergic Rhinitis",[2052,2052],{"nctId":2070,"briefTitle":2071,"status":224,"phases":2072,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":264,"conditions":2076,"interventions":2078},"NCT07436221","A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma",[87],"2026-12-27","2027-02-26","2026-02-28",[2077],"Asthma",[2052,2052,2052],{"nctId":2080,"briefTitle":2081,"status":224,"phases":2082,"primaryCompletion":1766,"completion":2083,"start":2084,"enrollment":2085,"conditions":2086,"interventions":2088},"NCT07502222","A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis",[87],"2028-01-10","2026-04-07",168,[2087],"Moderate-to-Severe Atopic Dermatitis",[2089,2052,2089,2052,2089,2089],"AK139 and placebo",{"trials":2091,"activeCount":97},[],{"trials":2093,"activeCount":97},[],{"trials":2095,"activeCount":97},[],{"intervention":396,"totalTrials":36,"cells":2097},{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2119,"PHASE3":2125,"PHASE4":2127,"NA":2129},{"trials":2099,"activeCount":97},[],{"trials":2101,"activeCount":13,"soonestReadout":2106},[2102,2112],{"nctId":2103,"briefTitle":2104,"status":174,"phases":2105,"primaryCompletion":2106,"completion":2107,"start":2108,"enrollment":2109,"conditions":2110,"interventions":2111},"NCT06929663","A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors",[86],"2026-11-05","2027-05-05","2025-07-02",48,[21],[396],{"nctId":2113,"briefTitle":2114,"status":174,"phases":2115,"primaryCompletion":2106,"completion":2107,"start":2116,"enrollment":392,"conditions":2117,"interventions":2118},"NCT07067567","A Study of AK146D1 for Injection in Advanced Solid Tumors",[86],"2025-08-07",[21],[396],{"trials":2120,"activeCount":135,"soonestReadout":389},[2121],{"nctId":386,"briefTitle":387,"status":224,"phases":2122,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":2123,"interventions":2124},[87],[394],[396,52],{"trials":2126,"activeCount":97},[],{"trials":2128,"activeCount":97},[],{"trials":2130,"activeCount":97},[],{"intervention":195,"totalTrials":22,"cells":2132},{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2159,"PHASE3":2177,"PHASE4":2179,"NA":2181},{"trials":2134,"activeCount":97},[],{"trials":2136,"activeCount":97},[2137,2141,2149],{"nctId":464,"briefTitle":465,"status":103,"phases":2138,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":2139,"interventions":2140},[86],[472],[195,47],{"nctId":2142,"briefTitle":2143,"status":103,"phases":2144,"primaryCompletion":2145,"completion":2145,"start":2146,"enrollment":397,"conditions":2147,"interventions":2148},"NCT05173792","Study of AK119 in Subjects With Advanced Solid Tumors",[86],"2023-05-22","2021-12-22",[30],[195],{"nctId":2150,"briefTitle":2151,"status":103,"phases":2152,"primaryCompletion":2153,"completion":2154,"start":2155,"enrollment":93,"conditions":2156,"interventions":2158},"NCT04516564","A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects",[86],"2021-05-04","2021-06-21","2020-09-28",[2157],"Coronavirus Disease 2019 (COVID-19)",[195],{"trials":2160,"activeCount":13,"soonestReadout":284},[2161,2165,2169,2173],{"nctId":185,"briefTitle":186,"status":174,"phases":2162,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":2163,"interventions":2164},[86,87],[193],[195,52],{"nctId":540,"briefTitle":541,"status":321,"phases":2166,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":2167,"interventions":2168},[86,87],[193],[195,47],{"nctId":281,"briefTitle":282,"status":126,"phases":2170,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":2171,"interventions":2172},[86,87],[289],[195,52,291,292,293,294],{"nctId":319,"briefTitle":320,"status":321,"phases":2174,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":2175,"interventions":2176},[86,87],[328],[195,52,330,122],{"trials":2178,"activeCount":97},[],{"trials":2180,"activeCount":97},[],{"trials":2182,"activeCount":97},[],{"intervention":209,"totalTrials":36,"cells":2184},{"EARLY_PHASE1":2185,"PHASE1":2187,"PHASE2":2189,"PHASE3":2203,"PHASE4":2205,"NA":2207},{"trials":2186,"activeCount":97},[],{"trials":2188,"activeCount":97},[],{"trials":2190,"activeCount":13,"soonestReadout":71},[2191,2195,2199],{"nctId":197,"briefTitle":198,"status":126,"phases":2192,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":2193,"interventions":2194},[86,87],[24],[52,206,122,207,208,209],{"nctId":69,"briefTitle":70,"status":174,"phases":2196,"primaryCompletion":71,"completion":572,"start":573,"enrollment":574,"conditions":2197,"interventions":2198},[87],[35],[47,47,209,577,578,579],{"nctId":1095,"briefTitle":1096,"status":103,"phases":2200,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":1101,"conditions":2201,"interventions":2202},[87],[33],[859,207,209,1104],{"trials":2204,"activeCount":97},[],{"trials":2206,"activeCount":97},[],{"trials":2208,"activeCount":97},[],{"intervention":786,"totalTrials":13,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2212,"activeCount":97},[],{"trials":2214,"activeCount":97},[],{"trials":2216,"activeCount":13,"soonestReadout":188},[2217,2221],{"nctId":1763,"briefTitle":1764,"status":174,"phases":2218,"primaryCompletion":1766,"completion":1767,"start":1768,"enrollment":274,"conditions":2219,"interventions":2220},[86,87],[1770],[786,206],{"nctId":776,"briefTitle":777,"status":174,"phases":2222,"primaryCompletion":188,"completion":779,"start":780,"enrollment":781,"conditions":2223,"interventions":2224},[86,87],[783,784,416,21],[786,330,220,122,786,340,787,648,788,220,340,244,786,789],{"trials":2226,"activeCount":97},[],{"trials":2228,"activeCount":97},[],{"trials":2230,"activeCount":97},[],{"intervention":79,"totalTrials":25,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2279,"PHASE4":2291,"NA":2293},{"trials":2234,"activeCount":97},[],{"trials":2236,"activeCount":97},[],{"trials":2238,"activeCount":135,"soonestReadout":75},[2239,2247,2255,2261,2270],{"nctId":2240,"briefTitle":2241,"status":321,"phases":2242,"primaryCompletion":2243,"completion":2243,"start":2244,"enrollment":135,"conditions":2245,"interventions":2246},"NCT05155020","A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma",[87],"2022-08-05","2022-02-11",[2077],[79,79,79],{"nctId":2248,"briefTitle":2249,"status":103,"phases":2250,"primaryCompletion":2251,"completion":2251,"start":2252,"enrollment":891,"conditions":2253,"interventions":2254},"NCT06092762","A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis",[87],"2024-11-13","2023-11-06",[19],[79],{"nctId":77,"briefTitle":78,"status":224,"phases":2256,"primaryCompletion":75,"completion":75,"start":2257,"enrollment":2258,"conditions":2259,"interventions":2260},[87],"2024-12-30",24,[19],[79],{"nctId":2262,"briefTitle":2263,"status":321,"phases":2264,"primaryCompletion":2265,"completion":2265,"start":2266,"enrollment":2267,"conditions":2268,"interventions":2269},"NCT05048056","Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis",[87],"2023-05-17","2021-09-30",79,[19],[79,79],{"nctId":2271,"briefTitle":2272,"status":103,"phases":2273,"primaryCompletion":2274,"completion":2274,"start":2275,"enrollment":2276,"conditions":2277,"interventions":2278},"NCT06035354","A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis",[86,87],"2024-06-21","2021-11-03",427,[19],[79,79,79,79,79,79,79,79],{"trials":2280,"activeCount":97},[2281],{"nctId":2282,"briefTitle":2283,"status":640,"phases":2284,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2289,"interventions":2290},"NCT06383468","A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis",[88],"2025-01-30","2026-01-30","2024-04-30",420,[19],[79],{"trials":2292,"activeCount":97},[],{"trials":2294,"activeCount":97},[],{"intervention":277,"totalTrials":36,"cells":2296},{"EARLY_PHASE1":2297,"PHASE1":2303,"PHASE2":2315,"PHASE3":2321,"PHASE4":2323,"NA":2325},{"trials":2298,"activeCount":97},[2299],{"nctId":451,"briefTitle":452,"status":103,"phases":2300,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":2301,"interventions":2302},[85],[459],[277,47],{"trials":2304,"activeCount":97},[2305],{"nctId":2306,"briefTitle":2307,"status":640,"phases":2308,"primaryCompletion":2309,"completion":2310,"start":2311,"enrollment":2312,"conditions":2313,"interventions":2314},"NCT05393063","A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors",[86],"2023-06","2024-06","2022-06",36,[21],[277],{"trials":2316,"activeCount":135,"soonestReadout":272},[2317],{"nctId":269,"briefTitle":270,"status":174,"phases":2318,"primaryCompletion":272,"completion":226,"start":273,"enrollment":274,"conditions":2319,"interventions":2320},[86,87],[16],[52,57,277,267,278,279],{"trials":2322,"activeCount":97},[],{"trials":2324,"activeCount":97},[],{"trials":2326,"activeCount":97},[],{"intervention":1936,"totalTrials":13,"cells":2328},{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2330,"activeCount":97},[],{"trials":2332,"activeCount":97},[],{"trials":2334,"activeCount":135,"soonestReadout":1550},[2335,2339],{"nctId":1927,"briefTitle":1928,"status":174,"phases":2336,"primaryCompletion":1550,"completion":1930,"start":1931,"enrollment":1932,"conditions":2337,"interventions":2338},[87],[1934],[1936,244,1937,1938],{"nctId":2340,"briefTitle":2341,"status":321,"phases":2342,"primaryCompletion":2343,"completion":2343,"start":2344,"enrollment":17,"conditions":2345,"interventions":2349},"NCT04999605","A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer",[86,87],"2022-06-10","2021-06-24",[157,2346,2347,2348],"Recurrent Ovarian Carcinoma","Relapsed Ovarian Cancer","Ovarian Cancer",[1936,2350,1938],"AK112 medium dose",{"trials":2352,"activeCount":97},[],{"trials":2354,"activeCount":97},[],{"trials":2356,"activeCount":97},[],{"intervention":1938,"totalTrials":13,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2373,"PHASE4":2375,"NA":2377},{"trials":2360,"activeCount":97},[],{"trials":2362,"activeCount":97},[],{"trials":2364,"activeCount":135,"soonestReadout":1550},[2365,2369],{"nctId":1927,"briefTitle":1928,"status":174,"phases":2366,"primaryCompletion":1550,"completion":1930,"start":1931,"enrollment":1932,"conditions":2367,"interventions":2368},[87],[1934],[1936,244,1937,1938],{"nctId":2340,"briefTitle":2341,"status":321,"phases":2370,"primaryCompletion":2343,"completion":2343,"start":2344,"enrollment":17,"conditions":2371,"interventions":2372},[86,87],[157,2346,2347,2348],[1936,2350,1938],{"trials":2374,"activeCount":97},[],{"trials":2376,"activeCount":97},[],{"trials":2378,"activeCount":97},[],{"intervention":121,"totalTrials":13,"cells":2380},{"EARLY_PHASE1":2381,"PHASE1":2383,"PHASE2":2389,"PHASE3":2395,"PHASE4":2397,"NA":2399},{"trials":2382,"activeCount":97},[],{"trials":2384,"activeCount":97},[2385],{"nctId":112,"briefTitle":113,"status":103,"phases":2386,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":2387,"interventions":2388},[86],[119],[52,121,122],{"trials":2390,"activeCount":135,"soonestReadout":368},[2391],{"nctId":886,"briefTitle":887,"status":174,"phases":2392,"primaryCompletion":368,"completion":889,"start":890,"enrollment":891,"conditions":2393,"interventions":2394},[87],[893],[895,57,206,121,122],{"trials":2396,"activeCount":97},[],{"trials":2398,"activeCount":97},[],{"trials":2400,"activeCount":97},[],{"intervention":625,"totalTrials":13,"cells":2402},{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2416,"PHASE3":2422,"PHASE4":2424,"NA":2426},{"trials":2404,"activeCount":97},[],{"trials":2406,"activeCount":97},[2407],{"nctId":2408,"briefTitle":2409,"status":103,"phases":2410,"primaryCompletion":2411,"completion":2412,"start":2413,"enrollment":144,"conditions":2414,"interventions":2415},"NCT04547205","A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors",[86],"2021-03-24","2022-10-31","2020-06-06",[30],[625],{"trials":2417,"activeCount":135,"soonestReadout":619},[2418],{"nctId":616,"briefTitle":617,"status":174,"phases":2419,"primaryCompletion":619,"completion":355,"start":620,"enrollment":621,"conditions":2420,"interventions":2421},[86,87],[623],[625,361,361,47],{"trials":2423,"activeCount":97},[],{"trials":2425,"activeCount":97},[],{"trials":2427,"activeCount":97},[],{"intervention":648,"totalTrials":13,"cells":2429},{"EARLY_PHASE1":2430,"PHASE1":2432,"PHASE2":2434,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2431,"activeCount":97},[],{"trials":2433,"activeCount":97},[],{"trials":2435,"activeCount":135,"soonestReadout":188},[2436,2440],{"nctId":776,"briefTitle":777,"status":174,"phases":2437,"primaryCompletion":188,"completion":779,"start":780,"enrollment":781,"conditions":2438,"interventions":2439},[86,87],[783,784,416,21],[786,330,220,122,786,340,787,648,788,220,340,244,786,789],{"nctId":638,"briefTitle":639,"status":640,"phases":2441,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":2442,"interventions":2443},[86,87],[24],[47,206,306,291,207,220,292,340,648],{"trials":2445,"activeCount":97},[],{"trials":2447,"activeCount":97},[],{"trials":2449,"activeCount":97},[],{"intervention":2451,"totalTrials":135,"cells":2452},"AK109+AK104",{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2457,"PHASE3":2467,"PHASE4":2469,"NA":2471},{"trials":2454,"activeCount":97},[],{"trials":2456,"activeCount":97},[],{"trials":2458,"activeCount":135,"soonestReadout":1829},[2459],{"nctId":2460,"briefTitle":2461,"status":174,"phases":2462,"primaryCompletion":1829,"completion":1829,"start":2275,"enrollment":2463,"conditions":2464,"interventions":2466},"NCT05142423","A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors",[86,87],198,[2465],"Advanced Solid Tumor",[2451],{"trials":2468,"activeCount":97},[],{"trials":2470,"activeCount":97},[],{"trials":2472,"activeCount":97},[],{"intervention":2474,"totalTrials":135,"cells":2475},"AK112, Cadonilimab, nab-paclitaxel, gemcitabine",{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2494,"PHASE4":2496,"NA":2498},{"trials":2477,"activeCount":97},[],{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":135,"soonestReadout":377},[2482],{"nctId":2483,"briefTitle":2484,"status":126,"phases":2485,"primaryCompletion":377,"completion":2486,"start":2487,"enrollment":2488,"conditions":2489,"interventions":2491},"NCT06646055","AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer",[86,87],"2027-12-30","2025-01-21",110,[2490],"Metastatic Pancreatic Ductal Adenocarcinoma",[2474,2474,2474,2492,2493],"AK112, nab-paclitaxel, gemcitabine","nab-paclitaxel, gemcitabine",{"trials":2495,"activeCount":97},[],{"trials":2497,"activeCount":97},[],{"trials":2499,"activeCount":97},[],{"intervention":2492,"totalTrials":135,"cells":2501},{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2512,"PHASE4":2514,"NA":2516},{"trials":2503,"activeCount":97},[],{"trials":2505,"activeCount":97},[],{"trials":2507,"activeCount":135,"soonestReadout":377},[2508],{"nctId":2483,"briefTitle":2484,"status":126,"phases":2509,"primaryCompletion":377,"completion":2486,"start":2487,"enrollment":2488,"conditions":2510,"interventions":2511},[86,87],[2490],[2474,2474,2474,2492,2493],{"trials":2513,"activeCount":97},[],{"trials":2515,"activeCount":97},[],{"trials":2517,"activeCount":97},[],{"intervention":2493,"totalTrials":135,"cells":2519},{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2530,"PHASE4":2532,"NA":2534},{"trials":2521,"activeCount":97},[],{"trials":2523,"activeCount":97},[],{"trials":2525,"activeCount":135,"soonestReadout":377},[2526],{"nctId":2483,"briefTitle":2484,"status":126,"phases":2527,"primaryCompletion":377,"completion":2486,"start":2487,"enrollment":2488,"conditions":2528,"interventions":2529},[86,87],[2490],[2474,2474,2474,2492,2493],{"trials":2531,"activeCount":97},[],{"trials":2533,"activeCount":97},[],{"trials":2535,"activeCount":97},[],{"intervention":183,"totalTrials":135,"cells":2537},{"EARLY_PHASE1":2538,"PHASE1":2540,"PHASE2":2542,"PHASE3":2548,"PHASE4":2550,"NA":2552},{"trials":2539,"activeCount":97},[],{"trials":2541,"activeCount":97},[],{"trials":2543,"activeCount":135,"soonestReadout":176},[2544],{"nctId":172,"briefTitle":173,"status":174,"phases":2545,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":2546,"interventions":2547},[87],[181],[183,47,52],{"trials":2549,"activeCount":97},[],{"trials":2551,"activeCount":97},[],{"trials":2553,"activeCount":97},[],{"intervention":2555,"totalTrials":135,"cells":2556},"AK127 in combination with AK112",{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2572,"PHASE4":2574,"NA":2576},{"trials":2558,"activeCount":97},[],{"trials":2560,"activeCount":97},[],{"trials":2562,"activeCount":135,"soonestReadout":237},[2563],{"nctId":2564,"briefTitle":2565,"status":126,"phases":2566,"primaryCompletion":237,"completion":2567,"start":2568,"enrollment":2569,"conditions":2570,"interventions":2571},"NCT05951608","A Phase Ib\u002FII Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors",[86,87],"2026-08-15","2023-10-16",216,[21],[2555],{"trials":2573,"activeCount":97},[],{"trials":2575,"activeCount":97},[],{"trials":2577,"activeCount":97},[],{"intervention":1259,"totalTrials":135,"cells":2579},{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2581,"activeCount":97},[],{"trials":2583,"activeCount":97},[],{"trials":2585,"activeCount":135,"soonestReadout":1254},[2586],{"nctId":1251,"briefTitle":1252,"status":224,"phases":2587,"primaryCompletion":1254,"completion":201,"start":1255,"enrollment":379,"conditions":2588,"interventions":2589},[87],[1257,16],[1259,1260],{"trials":2591,"activeCount":97},[],{"trials":2593,"activeCount":97},[],{"trials":2595,"activeCount":97},[],{"intervention":1937,"totalTrials":135,"cells":2597},{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2608,"PHASE4":2610,"NA":2612},{"trials":2599,"activeCount":97},[],{"trials":2601,"activeCount":97},[],{"trials":2603,"activeCount":135,"soonestReadout":1550},[2604],{"nctId":1927,"briefTitle":1928,"status":174,"phases":2605,"primaryCompletion":1550,"completion":1930,"start":1931,"enrollment":1932,"conditions":2606,"interventions":2607},[87],[1934],[1936,244,1937,1938],{"trials":2609,"activeCount":97},[],{"trials":2611,"activeCount":97},[],{"trials":2613,"activeCount":97},[],{"intervention":569,"totalTrials":135,"cells":2615},{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2626,"PHASE4":2628,"NA":2630},{"trials":2617,"activeCount":97},[],{"trials":2619,"activeCount":97},[],{"trials":2621,"activeCount":135,"soonestReadout":563},[2622],{"nctId":560,"briefTitle":561,"status":174,"phases":2623,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":2624,"interventions":2625},[87],[567],[47,569],{"trials":2627,"activeCount":97},[],{"trials":2629,"activeCount":97},[],{"trials":2631,"activeCount":97},[],{"intervention":256,"totalTrials":135,"cells":2633},{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2638,"PHASE3":2644,"PHASE4":2646,"NA":2648},{"trials":2635,"activeCount":97},[],{"trials":2637,"activeCount":97},[],{"trials":2639,"activeCount":135,"soonestReadout":249},[2640],{"nctId":246,"briefTitle":247,"status":224,"phases":2641,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":2642,"interventions":2643},[86,87],[254],[256,52],{"trials":2645,"activeCount":97},[],{"trials":2647,"activeCount":97},[],{"trials":2649,"activeCount":97},[],{"intervention":578,"totalTrials":135,"cells":2651},{"EARLY_PHASE1":2652,"PHASE1":2654,"PHASE2":2656,"PHASE3":2662,"PHASE4":2664,"NA":2666},{"trials":2653,"activeCount":97},[],{"trials":2655,"activeCount":97},[],{"trials":2657,"activeCount":135,"soonestReadout":71},[2658],{"nctId":69,"briefTitle":70,"status":174,"phases":2659,"primaryCompletion":71,"completion":572,"start":573,"enrollment":574,"conditions":2660,"interventions":2661},[87],[35],[47,47,209,577,578,579],{"trials":2663,"activeCount":97},[],{"trials":2665,"activeCount":97},[],{"trials":2667,"activeCount":97},[],{"intervention":579,"totalTrials":135,"cells":2669},{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2674,"PHASE3":2680,"PHASE4":2682,"NA":2684},{"trials":2671,"activeCount":97},[],{"trials":2673,"activeCount":97},[],{"trials":2675,"activeCount":135,"soonestReadout":71},[2676],{"nctId":69,"briefTitle":70,"status":174,"phases":2677,"primaryCompletion":71,"completion":572,"start":573,"enrollment":574,"conditions":2678,"interventions":2679},[87],[35],[47,47,209,577,578,579],{"trials":2681,"activeCount":97},[],{"trials":2683,"activeCount":97},[],{"trials":2685,"activeCount":97},[],{"intervention":787,"totalTrials":135,"cells":2687},{"EARLY_PHASE1":2688,"PHASE1":2690,"PHASE2":2692,"PHASE3":2698,"PHASE4":2700,"NA":2702},{"trials":2689,"activeCount":97},[],{"trials":2691,"activeCount":97},[],{"trials":2693,"activeCount":135,"soonestReadout":188},[2694],{"nctId":776,"briefTitle":777,"status":174,"phases":2695,"primaryCompletion":188,"completion":779,"start":780,"enrollment":781,"conditions":2696,"interventions":2697},[86,87],[783,784,416,21],[786,330,220,122,786,340,787,648,788,220,340,244,786,789],{"trials":2699,"activeCount":97},[],{"trials":2701,"activeCount":97},[],{"trials":2703,"activeCount":97},[],{"intervention":788,"totalTrials":135,"cells":2705},{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2716,"PHASE4":2718,"NA":2720},{"trials":2707,"activeCount":97},[],{"trials":2709,"activeCount":97},[],{"trials":2711,"activeCount":135,"soonestReadout":188},[2712],{"nctId":776,"briefTitle":777,"status":174,"phases":2713,"primaryCompletion":188,"completion":779,"start":780,"enrollment":781,"conditions":2714,"interventions":2715},[86,87],[783,784,416,21],[786,330,220,122,786,340,787,648,788,220,340,244,786,789],{"trials":2717,"activeCount":97},[],{"trials":2719,"activeCount":97},[],{"trials":2721,"activeCount":97},[],{"intervention":278,"totalTrials":135,"cells":2723},{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2725,"activeCount":97},[],{"trials":2727,"activeCount":97},[],{"trials":2729,"activeCount":135,"soonestReadout":272},[2730],{"nctId":269,"briefTitle":270,"status":174,"phases":2731,"primaryCompletion":272,"completion":226,"start":273,"enrollment":274,"conditions":2732,"interventions":2733},[86,87],[16],[52,57,277,267,278,279],{"trials":2735,"activeCount":97},[],{"trials":2737,"activeCount":97},[],{"trials":2739,"activeCount":97},[],{"intervention":279,"totalTrials":135,"cells":2741},{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2752,"PHASE4":2754,"NA":2756},{"trials":2743,"activeCount":97},[],{"trials":2745,"activeCount":97},[],{"trials":2747,"activeCount":135,"soonestReadout":272},[2748],{"nctId":269,"briefTitle":270,"status":174,"phases":2749,"primaryCompletion":272,"completion":226,"start":273,"enrollment":274,"conditions":2750,"interventions":2751},[86,87],[16],[52,57,277,267,278,279],{"trials":2753,"activeCount":97},[],{"trials":2755,"activeCount":97},[],{"trials":2757,"activeCount":97},[],{"intervention":294,"totalTrials":135,"cells":2759},{"EARLY_PHASE1":2760,"PHASE1":2762,"PHASE2":2764,"PHASE3":2770,"PHASE4":2772,"NA":2774},{"trials":2761,"activeCount":97},[],{"trials":2763,"activeCount":97},[],{"trials":2765,"activeCount":135,"soonestReadout":284},[2766],{"nctId":281,"briefTitle":282,"status":126,"phases":2767,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":2768,"interventions":2769},[86,87],[289],[195,52,291,292,293,294],{"trials":2771,"activeCount":97},[],{"trials":2773,"activeCount":97},[],{"trials":2775,"activeCount":97},[],{"intervention":1189,"totalTrials":135,"cells":2777},{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2788,"PHASE4":2790,"NA":2792},{"trials":2779,"activeCount":97},[],{"trials":2781,"activeCount":97},[],{"trials":2783,"activeCount":135,"soonestReadout":1181},[2784],{"nctId":1178,"briefTitle":1179,"status":224,"phases":2785,"primaryCompletion":1181,"completion":1182,"start":1183,"enrollment":1184,"conditions":2786,"interventions":2787},[86,87],[1186],[1188,895,1189],{"trials":2789,"activeCount":97},[],{"trials":2791,"activeCount":97},[],{"trials":2793,"activeCount":97},[],{"intervention":307,"totalTrials":135,"cells":2795},{"EARLY_PHASE1":2796,"PHASE1":2798,"PHASE2":2800,"PHASE3":2806,"PHASE4":2808,"NA":2810},{"trials":2797,"activeCount":97},[],{"trials":2799,"activeCount":97},[],{"trials":2801,"activeCount":135,"soonestReadout":299},[2802],{"nctId":296,"briefTitle":297,"status":126,"phases":2803,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":2804,"interventions":2805},[87],[304],[52,206,291,306,292,307,308],{"trials":2807,"activeCount":97},[],{"trials":2809,"activeCount":97},[],{"trials":2811,"activeCount":97},[],{"intervention":911,"totalTrials":135,"cells":2813},{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2824,"PHASE4":2826,"NA":2828},{"trials":2815,"activeCount":97},[],{"trials":2817,"activeCount":97},[],{"trials":2819,"activeCount":135,"soonestReadout":56},[2820],{"nctId":54,"briefTitle":55,"status":174,"phases":2821,"primaryCompletion":56,"completion":906,"start":907,"enrollment":216,"conditions":2822,"interventions":2823},[87],[909],[57,206,291,911,340,208],{"trials":2825,"activeCount":97},[],{"trials":2827,"activeCount":97},[],{"trials":2829,"activeCount":97},[],{"intervention":664,"totalTrials":135,"cells":2831},{"EARLY_PHASE1":2832,"PHASE1":2834,"PHASE2":2836,"PHASE3":2842,"PHASE4":2844,"NA":2846},{"trials":2833,"activeCount":97},[],{"trials":2835,"activeCount":97},[],{"trials":2837,"activeCount":135,"soonestReadout":314},[2838],{"nctId":654,"briefTitle":655,"status":126,"phases":2839,"primaryCompletion":314,"completion":657,"start":658,"enrollment":659,"conditions":2840,"interventions":2841},[87],[661,662],[47,664],{"trials":2843,"activeCount":97},[],{"trials":2845,"activeCount":97},[],{"trials":2847,"activeCount":97},[],{"intervention":1834,"totalTrials":135,"cells":2849},{"EARLY_PHASE1":2850,"PHASE1":2852,"PHASE2":2854,"PHASE3":2860,"PHASE4":2862,"NA":2864},{"trials":2851,"activeCount":97},[],{"trials":2853,"activeCount":97},[],{"trials":2855,"activeCount":135,"soonestReadout":1828},[2856],{"nctId":1825,"briefTitle":1826,"status":224,"phases":2857,"primaryCompletion":1828,"completion":1829,"start":1830,"enrollment":891,"conditions":2858,"interventions":2859},[86,87],[1832],[206,1785,1834],{"trials":2861,"activeCount":97},[],{"trials":2863,"activeCount":97},[],{"trials":2865,"activeCount":97},[],{"intervention":384,"totalTrials":135,"cells":2867},{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2878,"PHASE4":2880,"NA":2882},{"trials":2869,"activeCount":97},[],{"trials":2871,"activeCount":97},[],{"trials":2873,"activeCount":135,"soonestReadout":377},[2874],{"nctId":374,"briefTitle":375,"status":126,"phases":2875,"primaryCompletion":377,"completion":201,"start":378,"enrollment":379,"conditions":2876,"interventions":2877},[87],[381,382],[206,52,384,361],{"trials":2879,"activeCount":97},[],{"trials":2881,"activeCount":97},[],{"trials":2883,"activeCount":97},[],{"intervention":2885,"totalTrials":135,"cells":2886},"Drug: AK129 Drug：oxaliplatin Drug：capecitabine",{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2902,"PHASE4":2904,"NA":2906},{"trials":2888,"activeCount":97},[],{"trials":2890,"activeCount":97},[],{"trials":2892,"activeCount":135,"soonestReadout":335},[2893],{"nctId":2894,"briefTitle":2895,"status":224,"phases":2896,"primaryCompletion":335,"completion":335,"start":2897,"enrollment":2898,"conditions":2899,"interventions":2900},"NCT06586294","A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G\u002F GEJ Adenocarcinoma",[86,87],"2024-09-10",294,[612,613],[2885,2901],"Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine",{"trials":2903,"activeCount":97},[],{"trials":2905,"activeCount":97},[],{"trials":2907,"activeCount":97},[],{"intervention":2901,"totalTrials":135,"cells":2909},{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2914,"PHASE3":2920,"PHASE4":2922,"NA":2924},{"trials":2911,"activeCount":97},[],{"trials":2913,"activeCount":97},[],{"trials":2915,"activeCount":135,"soonestReadout":335},[2916],{"nctId":2894,"briefTitle":2895,"status":224,"phases":2917,"primaryCompletion":335,"completion":335,"start":2897,"enrollment":2898,"conditions":2918,"interventions":2919},[86,87],[612,613],[2885,2901],{"trials":2921,"activeCount":97},[],{"trials":2923,"activeCount":97},[],{"trials":2925,"activeCount":97},[],{"intervention":2089,"totalTrials":135,"cells":2927},{"EARLY_PHASE1":2928,"PHASE1":2930,"PHASE2":2932,"PHASE3":2938,"PHASE4":2940,"NA":2942},{"trials":2929,"activeCount":97},[],{"trials":2931,"activeCount":97},[],{"trials":2933,"activeCount":135,"soonestReadout":1766},[2934],{"nctId":2080,"briefTitle":2081,"status":224,"phases":2935,"primaryCompletion":1766,"completion":2083,"start":2084,"enrollment":2085,"conditions":2936,"interventions":2937},[87],[2087],[2089,2052,2089,2052,2089,2089],{"trials":2939,"activeCount":97},[],{"trials":2941,"activeCount":97},[],{"trials":2943,"activeCount":97},[],{"intervention":67,"totalTrials":13,"cells":2945},{"EARLY_PHASE1":2946,"PHASE1":2948,"PHASE2":2967,"PHASE3":2969,"PHASE4":2971,"NA":2973},{"trials":2947,"activeCount":97},[],{"trials":2949,"activeCount":13,"soonestReadout":66},[2950,2960],{"nctId":2951,"briefTitle":2952,"status":224,"phases":2953,"primaryCompletion":2954,"completion":2954,"start":2955,"enrollment":2956,"conditions":2957,"interventions":2959},"NCT07043283","A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects",[86],"2026-04-30","2025-07-01",204,[2958],"Healthy Subjects",[67],{"nctId":64,"briefTitle":65,"status":224,"phases":2961,"primaryCompletion":66,"completion":2962,"start":2963,"enrollment":891,"conditions":2964,"interventions":2966},[86],"2025-06-17","2024-11-04",[2965],"Healthy Subjects (HS)",[67,67],{"trials":2968,"activeCount":97},[],{"trials":2970,"activeCount":97},[],{"trials":2972,"activeCount":97},[],{"trials":2974,"activeCount":97},[],{"intervention":2976,"totalTrials":25,"cells":2977},"AK111",{"EARLY_PHASE1":2978,"PHASE1":2980,"PHASE2":2997,"PHASE3":3020,"PHASE4":3040,"NA":3042},{"trials":2979,"activeCount":97},[],{"trials":2981,"activeCount":135,"soonestReadout":2286},[2982,2990],{"nctId":2983,"briefTitle":2984,"status":103,"phases":2985,"primaryCompletion":2986,"completion":2986,"start":2987,"enrollment":2109,"conditions":2988,"interventions":2989},"NCT05504317","A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis",[86],"2021-03-02","2020-05-28",[27],[2976],{"nctId":2991,"briefTitle":2992,"status":224,"phases":2993,"primaryCompletion":2286,"completion":2286,"start":2994,"enrollment":2109,"conditions":2995,"interventions":2996},"NCT06947109","A Clinical Study of AK139 in Healthy Subjects",[86],"2025-05-06",[2958],[2976],{"trials":2998,"activeCount":97},[2999,3009],{"nctId":3000,"briefTitle":3001,"status":103,"phases":3002,"primaryCompletion":3003,"completion":3003,"start":3004,"enrollment":3005,"conditions":3006,"interventions":3008},"NCT06061471","To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis",[87],"2024-12-11","2023-09-22",454,[27,3007],"Skin Diseases",[2976,2976],{"nctId":3010,"briefTitle":3011,"status":103,"phases":3012,"primaryCompletion":3013,"completion":3014,"start":3015,"enrollment":3016,"conditions":3017,"interventions":3019},"NCT05467995","A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis",[87],"2022-04-25","2022-05-19","2021-06-02",125,[3018],"Ankylosing Spondylitis",[2976],{"trials":3021,"activeCount":97},[3022,3031],{"nctId":3023,"briefTitle":3024,"status":103,"phases":3025,"primaryCompletion":3026,"completion":3026,"start":3027,"enrollment":3028,"conditions":3029,"interventions":3030},"NCT06066125","A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis",[88],"2024-08-19","2023-03-31",351,[27,3007],[2976,2976],{"nctId":3032,"briefTitle":3033,"status":103,"phases":3034,"primaryCompletion":3035,"completion":3036,"start":3037,"enrollment":1552,"conditions":3038,"interventions":3039},"NCT06378697","A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis",[88],"2025-02-19","2025-11-07","2023-11-22",[3018],[2976],{"trials":3041,"activeCount":97},[],{"trials":3043,"activeCount":97},[],{"intervention":3045,"totalTrials":135,"cells":3046},"AK132",{"EARLY_PHASE1":3047,"PHASE1":3049,"PHASE2":3060,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3048,"activeCount":97},[],{"trials":3050,"activeCount":135,"soonestReadout":3055},[3051],{"nctId":3052,"briefTitle":3053,"status":224,"phases":3054,"primaryCompletion":3055,"completion":3056,"start":1963,"enrollment":252,"conditions":3057,"interventions":3059},"NCT06166472","A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor",[86],"2026-04-24","2026-07-24",[3058],"Advanced Malignant Solid Tumor",[3045],{"trials":3061,"activeCount":97},[],{"trials":3063,"activeCount":97},[],{"trials":3065,"activeCount":97},[],{"trials":3067,"activeCount":97},[],{"intervention":3069,"totalTrials":135,"cells":3070},"AK127 Q3W IV infusion ,AK104 10mg\u002Fkg Q3W IV",{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3085,"PHASE3":3087,"PHASE4":3089,"NA":3091},{"trials":3072,"activeCount":97},[],{"trials":3074,"activeCount":135,"soonestReadout":3079},[3075],{"nctId":3076,"briefTitle":3077,"status":174,"phases":3078,"primaryCompletion":3079,"completion":3080,"start":3081,"enrollment":3082,"conditions":3083,"interventions":3084},"NCT05868876","A Phase Ia\u002FIb Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors",[86],"2025-11","2026-02","2023-06-29",205,[24],[3069],{"trials":3086,"activeCount":97},[],{"trials":3088,"activeCount":97},[],{"trials":3090,"activeCount":97},[],{"trials":3092,"activeCount":97},[],{"intervention":3094,"totalTrials":135,"cells":3095},"AK135",{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3108,"PHASE3":3110,"PHASE4":3112,"NA":3114},{"trials":3097,"activeCount":97},[],{"trials":3099,"activeCount":135,"soonestReadout":692},[3100],{"nctId":3101,"briefTitle":3102,"status":224,"phases":3103,"primaryCompletion":692,"completion":177,"start":61,"enrollment":3104,"conditions":3105,"interventions":3107},"NCT06860789","AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)",[86],85,[3106],"Chemotherapy-induced Peripheral Neuropathy (CIPN)",[3094],{"trials":3109,"activeCount":97},[],{"trials":3111,"activeCount":97},[],{"trials":3113,"activeCount":97},[],{"trials":3115,"activeCount":97},[],{"intervention":3117,"totalTrials":135,"cells":3118},"AK131",{"EARLY_PHASE1":3119,"PHASE1":3121,"PHASE2":3131,"PHASE3":3133,"PHASE4":3135,"NA":3137},{"trials":3120,"activeCount":97},[],{"trials":3122,"activeCount":135,"soonestReadout":3127},[3123],{"nctId":3124,"briefTitle":3125,"status":174,"phases":3126,"primaryCompletion":3127,"completion":434,"start":3128,"enrollment":645,"conditions":3129,"interventions":3130},"NCT06166888","A Study of AK131 in Patients With Advanced Solid Tumors",[86],"2026-08","2024-01-10",[30],[3117],{"trials":3132,"activeCount":97},[],{"trials":3134,"activeCount":97},[],{"trials":3136,"activeCount":97},[],{"trials":3138,"activeCount":97},[],{"intervention":881,"totalTrials":135,"cells":3140},{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3149,"PHASE3":3151,"PHASE4":3153,"NA":3155},{"trials":3142,"activeCount":97},[],{"trials":3144,"activeCount":135,"soonestReadout":874},[3145],{"nctId":871,"briefTitle":872,"status":224,"phases":3146,"primaryCompletion":874,"completion":875,"start":876,"enrollment":229,"conditions":3147,"interventions":3148},[86],[878,879],[881,57,42,882],{"trials":3150,"activeCount":97},[],{"trials":3152,"activeCount":97},[],{"trials":3154,"activeCount":97},[],{"trials":3156,"activeCount":97},[],{"intervention":882,"totalTrials":135,"cells":3158},{"EARLY_PHASE1":3159,"PHASE1":3161,"PHASE2":3167,"PHASE3":3169,"PHASE4":3171,"NA":3173},{"trials":3160,"activeCount":97},[],{"trials":3162,"activeCount":135,"soonestReadout":874},[3163],{"nctId":871,"briefTitle":872,"status":224,"phases":3164,"primaryCompletion":874,"completion":875,"start":876,"enrollment":229,"conditions":3165,"interventions":3166},[86],[878,879],[881,57,42,882],{"trials":3168,"activeCount":97},[],{"trials":3170,"activeCount":97},[],{"trials":3172,"activeCount":97},[],{"trials":3174,"activeCount":97},[],{"intervention":3176,"totalTrials":135,"cells":3177},"AK150",{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3192,"PHASE3":3194,"PHASE4":3196,"NA":3198},{"trials":3179,"activeCount":97},[],{"trials":3181,"activeCount":135,"soonestReadout":3186},[3182],{"nctId":3183,"briefTitle":3184,"status":224,"phases":3185,"primaryCompletion":3186,"completion":3187,"start":2954,"enrollment":3188,"conditions":3189,"interventions":3191},"NCT07566247","A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor",[86],"2029-02-21","2029-06-07",96,[3190],"Advanced Malignant Solid Tumors",[3176],{"trials":3193,"activeCount":97},[],{"trials":3195,"activeCount":97},[],{"trials":3197,"activeCount":97},[],{"trials":3199,"activeCount":97},[],{"intervention":3201,"totalTrials":135,"cells":3202},"AK152",{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3214,"PHASE3":3216,"PHASE4":3218,"NA":3220},{"trials":3204,"activeCount":97},[],{"trials":3206,"activeCount":135,"soonestReadout":189},[3207],{"nctId":3208,"briefTitle":3209,"status":224,"phases":3210,"primaryCompletion":189,"completion":189,"start":572,"enrollment":131,"conditions":3211,"interventions":3213},"NCT07301502","A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease",[86],[3212],"Alzheimer' s Disease",[3201],{"trials":3215,"activeCount":97},[],{"trials":3217,"activeCount":97},[],{"trials":3219,"activeCount":97},[],{"trials":3221,"activeCount":97},[],{"intervention":3223,"totalTrials":135,"cells":3224},"AK137",{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3236,"PHASE3":3238,"PHASE4":3240,"NA":3242},{"trials":3226,"activeCount":97},[],{"trials":3228,"activeCount":135,"soonestReadout":367},[3229],{"nctId":3230,"briefTitle":3231,"status":224,"phases":3232,"primaryCompletion":367,"completion":261,"start":3233,"enrollment":191,"conditions":3234,"interventions":3235},"NCT06691360","AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors",[86],"2024-12",[24],[3223],{"trials":3237,"activeCount":97},[],{"trials":3239,"activeCount":97},[],{"trials":3241,"activeCount":97},[],{"trials":3243,"activeCount":97},[],{"intervention":3245,"totalTrials":135,"cells":3246},"AK129 IV",{"EARLY_PHASE1":3247,"PHASE1":3249,"PHASE2":3260,"PHASE3":3262,"PHASE4":3264,"NA":3266},{"trials":3248,"activeCount":97},[],{"trials":3250,"activeCount":135,"soonestReadout":3080},[3251],{"nctId":3252,"briefTitle":3253,"status":174,"phases":3254,"primaryCompletion":3080,"completion":272,"start":3255,"enrollment":3256,"conditions":3257,"interventions":3259},"NCT05645276","A Study of AK129 in Patients With Advanced Malignant Tumors",[86],"2023-03-02",182,[3258],"Advanced Malignant Tumors(Stage IA-IB)",[3245],{"trials":3261,"activeCount":97},[],{"trials":3263,"activeCount":97},[],{"trials":3265,"activeCount":97},[],{"trials":3267,"activeCount":97},[],{"intervention":859,"totalTrials":22,"cells":3269},{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3274,"PHASE3":3322,"PHASE4":3332,"NA":3334},{"trials":3271,"activeCount":97},[],{"trials":3273,"activeCount":97},[],{"trials":3275,"activeCount":97},[3276,3287,3291,3300,3311],{"nctId":3277,"briefTitle":3278,"status":103,"phases":3279,"primaryCompletion":3280,"completion":3281,"start":3282,"enrollment":3283,"conditions":3284,"interventions":3285},"NCT04172571","A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)",[87],"2022-06-01","2022-07-08","2018-11-22",31,[16],[859,3286],"Anlotinib Hydrochloride",{"nctId":1095,"briefTitle":1096,"status":103,"phases":3288,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":1101,"conditions":3289,"interventions":3290},[87],[33],[859,207,209,1104],{"nctId":3292,"briefTitle":3293,"status":103,"phases":3294,"primaryCompletion":3295,"completion":3296,"start":3297,"enrollment":645,"conditions":3298,"interventions":3299},"NCT03866967","A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma",[87],"2021-03-13","2024-03-22","2019-03-27",[33],[859],{"nctId":3301,"briefTitle":3302,"status":103,"phases":3303,"primaryCompletion":3304,"completion":3305,"start":3306,"enrollment":3307,"conditions":3308,"interventions":3310},"NCT03722147","A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma",[86,87],"2020-01-10","2021-12-31","2018-08-13",94,[3309],"Hodgkin's Lymphoma",[859],{"nctId":3312,"briefTitle":3313,"status":103,"phases":3314,"primaryCompletion":3315,"completion":3316,"start":3317,"enrollment":3318,"conditions":3319,"interventions":3321},"NCT04172506","A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors",[86,87],"2021-12-01","2022-01-30","2019-09-10",65,[30,3320,1257],"Lung Cancer",[859],{"trials":3323,"activeCount":97},[3324,3328],{"nctId":1010,"briefTitle":1011,"status":321,"phases":3325,"primaryCompletion":1013,"completion":1014,"start":1015,"enrollment":1016,"conditions":3326,"interventions":3327},[88],[856],[859,725,362,1019],{"nctId":848,"briefTitle":849,"status":103,"phases":3329,"primaryCompletion":851,"completion":852,"start":853,"enrollment":854,"conditions":3330,"interventions":3331},[88],[856,857],[859,220,122],{"trials":3333,"activeCount":97},[],{"trials":3335,"activeCount":97},[],{"intervention":3337,"totalTrials":22,"cells":3338},"AK102",{"EARLY_PHASE1":3339,"PHASE1":3341,"PHASE2":3351,"PHASE3":3385,"PHASE4":3414,"NA":3416},{"trials":3340,"activeCount":97},[],{"trials":3342,"activeCount":97},[3343],{"nctId":3344,"briefTitle":3345,"status":103,"phases":3346,"primaryCompletion":3282,"completion":3282,"start":3347,"enrollment":446,"conditions":3348,"interventions":3350},"NCT04169386","A Study of PCSK9 Inhibitor AK102 in Healthy Subjects",[86],"2018-05-23",[3349],"Hypercholesterolaemia",[3337],{"trials":3352,"activeCount":97},[3353,3364,3375],{"nctId":3354,"briefTitle":3355,"status":103,"phases":3356,"primaryCompletion":3357,"completion":3357,"start":3358,"enrollment":3359,"conditions":3360,"interventions":3362},"NCT04173793","A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)",[87],"2022-09-26","2019-11-18",109,[3361],"Heterozygous Familial Hypercholesterolemia",[3337,3363],"Statins and\u002For Ezetimibe",{"nctId":3365,"briefTitle":3366,"status":103,"phases":3367,"primaryCompletion":3368,"completion":3368,"start":3369,"enrollment":1839,"conditions":3370,"interventions":3372},"NCT03933293","A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH",[87],"2021-03-15","2019-05-13",[3371],"Homozygous Familial Hypercholesterolemia",[3337,3373,3374],"Statins","Ezetimibe",{"nctId":3376,"briefTitle":3377,"status":103,"phases":3378,"primaryCompletion":1100,"completion":1100,"start":3379,"enrollment":3380,"conditions":3381,"interventions":3383},"NCT04358432","A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia",[87],"2020-05-13",262,[3382],"Hypercholesterolemia",[3337,3384,3363],"Placebos",{"trials":3386,"activeCount":97},[3387,3396,3405],{"nctId":3388,"briefTitle":3389,"status":103,"phases":3390,"primaryCompletion":3391,"completion":3391,"start":2275,"enrollment":3392,"conditions":3393,"interventions":3395},"NCT05255094","A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia",[88],"2022-06-22",464,[3394],"Hyperlipidemia",[3337,3337],{"nctId":3397,"briefTitle":3398,"status":103,"phases":3399,"primaryCompletion":3400,"completion":3400,"start":3401,"enrollment":3402,"conditions":3403,"interventions":3404},"NCT05260411","A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia",[88],"2022-12-19","2022-01-26",246,[3394],[3337,3337],{"nctId":3406,"briefTitle":3407,"status":103,"phases":3408,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":3411,"conditions":3412,"interventions":3413},"NCT05255458","A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia",[88],"2023-01-09","2021-11-04",122,[3394],[3337],{"trials":3415,"activeCount":97},[],{"trials":3417,"activeCount":97},[],{"intervention":3419,"totalTrials":36,"cells":3420},"AK101",{"EARLY_PHASE1":3421,"PHASE1":3423,"PHASE2":3425,"PHASE3":3445,"PHASE4":3457,"NA":3459},{"trials":3422,"activeCount":97},[],{"trials":3424,"activeCount":97},[],{"trials":3426,"activeCount":97},[3427,3436],{"nctId":3428,"briefTitle":3429,"status":103,"phases":3430,"primaryCompletion":3431,"completion":3431,"start":3432,"enrollment":3188,"conditions":3433,"interventions":3435},"NCT04172233","A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis",[86,87],"2019-10-31","2018-01-09",[3434],"Plaque Psoriasis",[3419],{"nctId":3437,"briefTitle":3438,"status":103,"phases":3439,"primaryCompletion":3440,"completion":3440,"start":3441,"enrollment":3442,"conditions":3443,"interventions":3444},"NCT04173637","Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis",[87],"2022-03-03","2019-12-19",330,[3434],[3419],{"trials":3446,"activeCount":97},[3447],{"nctId":3448,"briefTitle":3449,"status":103,"phases":3450,"primaryCompletion":3451,"completion":3451,"start":3452,"enrollment":3453,"conditions":3454,"interventions":3456},"NCT05120297","A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis",[88],"2022-09-29","2021-11-29",452,[3455],"Psoriasis Vulgaris",[3419],{"trials":3458,"activeCount":97},[],{"trials":3460,"activeCount":97},[],{"intervention":3462,"totalTrials":135,"cells":3463},"AK101 injection SC",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3470,"PHASE4":3481,"NA":3483},{"trials":3465,"activeCount":97},[],{"trials":3467,"activeCount":97},[],{"trials":3469,"activeCount":97},[],{"trials":3471,"activeCount":97},[3472],{"nctId":3473,"briefTitle":3474,"status":103,"phases":3475,"primaryCompletion":3476,"completion":3476,"start":3477,"enrollment":3478,"conditions":3479,"interventions":3480},"NCT05509361","Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis",[88],"2023-11-24","2022-04-08",950,[3434],[3462],{"trials":3482,"activeCount":97},[],{"trials":3484,"activeCount":97},[],{"intervention":1019,"totalTrials":135,"cells":3486},{"EARLY_PHASE1":3487,"PHASE1":3489,"PHASE2":3491,"PHASE3":3493,"PHASE4":3499,"NA":3501},{"trials":3488,"activeCount":97},[],{"trials":3490,"activeCount":97},[],{"trials":3492,"activeCount":97},[],{"trials":3494,"activeCount":97},[3495],{"nctId":1010,"briefTitle":1011,"status":321,"phases":3496,"primaryCompletion":1013,"completion":1014,"start":1015,"enrollment":1016,"conditions":3497,"interventions":3498},[88],[856],[859,725,362,1019],{"trials":3500,"activeCount":97},[],{"trials":3502,"activeCount":97},[],{"intervention":1338,"totalTrials":135,"cells":3504},{"EARLY_PHASE1":3505,"PHASE1":3507,"PHASE2":3509,"PHASE3":3511,"PHASE4":3517,"NA":3519},{"trials":3506,"activeCount":97},[],{"trials":3508,"activeCount":97},[],{"trials":3510,"activeCount":97},[],{"trials":3512,"activeCount":97},[3513],{"nctId":1330,"briefTitle":1331,"status":640,"phases":3514,"primaryCompletion":619,"completion":1333,"start":1334,"enrollment":229,"conditions":3515,"interventions":3516},[88],[1336],[789,1338],{"trials":3518,"activeCount":97},[],{"trials":3520,"activeCount":97},[],{"intervention":3363,"totalTrials":36,"cells":3522},{"EARLY_PHASE1":3523,"PHASE1":3525,"PHASE2":3527,"PHASE3":3549,"PHASE4":3551,"NA":3553},{"trials":3524,"activeCount":97},[],{"trials":3526,"activeCount":97},[],{"trials":3528,"activeCount":97},[3529,3533,3545],{"nctId":3354,"briefTitle":3355,"status":103,"phases":3530,"primaryCompletion":3357,"completion":3357,"start":3358,"enrollment":3359,"conditions":3531,"interventions":3532},[87],[3361],[3337,3363],{"nctId":3534,"briefTitle":3535,"status":103,"phases":3536,"primaryCompletion":3537,"completion":3537,"start":3538,"enrollment":3539,"conditions":3540,"interventions":3541},"NCT04173403","A Long-term Study of AK102 in Patients With Hypercholesterolemia",[87],"2023-02-17","2019-11-04",796,[3382],[3542,3543,3544,3363],"450mg AK102","300mg AK102","150mg AK102",{"nctId":3376,"briefTitle":3377,"status":103,"phases":3546,"primaryCompletion":1100,"completion":1100,"start":3379,"enrollment":3380,"conditions":3547,"interventions":3548},[87],[3382],[3337,3384,3363],{"trials":3550,"activeCount":97},[],{"trials":3552,"activeCount":97},[],{"trials":3554,"activeCount":97},[],{"intervention":3286,"totalTrials":13,"cells":3556},{"EARLY_PHASE1":3557,"PHASE1":3559,"PHASE2":3561,"PHASE3":3571,"PHASE4":3573,"NA":3575},{"trials":3558,"activeCount":97},[],{"trials":3560,"activeCount":97},[],{"trials":3562,"activeCount":97},[3563,3567],{"nctId":3277,"briefTitle":3278,"status":103,"phases":3564,"primaryCompletion":3280,"completion":3281,"start":3282,"enrollment":3283,"conditions":3565,"interventions":3566},[87],[16],[859,3286],{"nctId":1095,"briefTitle":1096,"status":103,"phases":3568,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":1101,"conditions":3569,"interventions":3570},[87],[33],[859,207,209,1104],{"trials":3572,"activeCount":97},[],{"trials":3574,"activeCount":97},[],{"trials":3576,"activeCount":97},[],{"intervention":3578,"totalTrials":135,"cells":3579},"AK120 300mg Q2W",{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3596,"PHASE4":3598,"NA":3600},{"trials":3581,"activeCount":97},[],{"trials":3583,"activeCount":97},[],{"trials":3585,"activeCount":97},[3586],{"nctId":3587,"briefTitle":3588,"status":103,"phases":3589,"primaryCompletion":3590,"completion":3591,"start":3592,"enrollment":3593,"conditions":3594,"interventions":3595},"NCT06700499","A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis",[87],"2025-07-31","2025-09-11","2024-07-08",450,[19],[3578],{"trials":3597,"activeCount":97},[],{"trials":3599,"activeCount":97},[],{"trials":3601,"activeCount":97},[],{"intervention":3603,"totalTrials":135,"cells":3604},"AK104 plus Carboplatin and Pemetrexed",{"EARLY_PHASE1":3605,"PHASE1":3607,"PHASE2":3609,"PHASE3":3621,"PHASE4":3623,"NA":3625},{"trials":3606,"activeCount":97},[],{"trials":3608,"activeCount":97},[],{"trials":3610,"activeCount":97},[3611],{"nctId":3612,"briefTitle":3613,"status":103,"phases":3614,"primaryCompletion":1014,"completion":1014,"start":3615,"enrollment":3616,"conditions":3617,"interventions":3619},"NCT04647344","A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer",[86,87],"2020-11-24",46,[3618],"Lung Cancer Non-Small Cell Stage IIIB\u002FIIIC\u002FIV",[3603,3620],"AK104 plus Carboplatin and paclitaxel",{"trials":3622,"activeCount":97},[],{"trials":3624,"activeCount":97},[],{"trials":3626,"activeCount":97},[],{"intervention":3620,"totalTrials":135,"cells":3628},{"EARLY_PHASE1":3629,"PHASE1":3631,"PHASE2":3633,"PHASE3":3639,"PHASE4":3641,"NA":3643},{"trials":3630,"activeCount":97},[],{"trials":3632,"activeCount":97},[],{"trials":3634,"activeCount":97},[3635],{"nctId":3612,"briefTitle":3613,"status":103,"phases":3636,"primaryCompletion":1014,"completion":1014,"start":3615,"enrollment":3616,"conditions":3637,"interventions":3638},[86,87],[3618],[3603,3620],{"trials":3640,"activeCount":97},[],{"trials":3642,"activeCount":97},[],{"trials":3644,"activeCount":97},[],{"intervention":3542,"totalTrials":135,"cells":3646},{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3657,"PHASE4":3659,"NA":3661},{"trials":3648,"activeCount":97},[],{"trials":3650,"activeCount":97},[],{"trials":3652,"activeCount":97},[3653],{"nctId":3534,"briefTitle":3535,"status":103,"phases":3654,"primaryCompletion":3537,"completion":3537,"start":3538,"enrollment":3539,"conditions":3655,"interventions":3656},[87],[3382],[3542,3543,3544,3363],{"trials":3658,"activeCount":97},[],{"trials":3660,"activeCount":97},[],{"trials":3662,"activeCount":97},[],{"intervention":3543,"totalTrials":135,"cells":3664},{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3669,"PHASE3":3675,"PHASE4":3677,"NA":3679},{"trials":3666,"activeCount":97},[],{"trials":3668,"activeCount":97},[],{"trials":3670,"activeCount":97},[3671],{"nctId":3534,"briefTitle":3535,"status":103,"phases":3672,"primaryCompletion":3537,"completion":3537,"start":3538,"enrollment":3539,"conditions":3673,"interventions":3674},[87],[3382],[3542,3543,3544,3363],{"trials":3676,"activeCount":97},[],{"trials":3678,"activeCount":97},[],{"trials":3680,"activeCount":97},[],{"intervention":3544,"totalTrials":135,"cells":3682},{"EARLY_PHASE1":3683,"PHASE1":3685,"PHASE2":3687,"PHASE3":3693,"PHASE4":3695,"NA":3697},{"trials":3684,"activeCount":97},[],{"trials":3686,"activeCount":97},[],{"trials":3688,"activeCount":97},[3689],{"nctId":3534,"briefTitle":3535,"status":103,"phases":3690,"primaryCompletion":3537,"completion":3537,"start":3538,"enrollment":3539,"conditions":3691,"interventions":3692},[87],[3382],[3542,3543,3544,3363],{"trials":3694,"activeCount":97},[],{"trials":3696,"activeCount":97},[],{"trials":3698,"activeCount":97},[],{"intervention":3700,"totalTrials":135,"cells":3701},"AK111\u002FPlacebo",{"EARLY_PHASE1":3702,"PHASE1":3704,"PHASE2":3706,"PHASE3":3717,"PHASE4":3719,"NA":3721},{"trials":3703,"activeCount":97},[],{"trials":3705,"activeCount":97},[],{"trials":3707,"activeCount":97},[3708],{"nctId":3709,"briefTitle":3710,"status":103,"phases":3711,"primaryCompletion":3712,"completion":3712,"start":3713,"enrollment":3714,"conditions":3715,"interventions":3716},"NCT05096364","A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis",[87],"2023-02-03","2021-04-28",251,[27],[3700],{"trials":3718,"activeCount":97},[],{"trials":3720,"activeCount":97},[],{"trials":3722,"activeCount":97},[],{"intervention":2350,"totalTrials":135,"cells":3724},{"EARLY_PHASE1":3725,"PHASE1":3727,"PHASE2":3729,"PHASE3":3735,"PHASE4":3737,"NA":3739},{"trials":3726,"activeCount":97},[],{"trials":3728,"activeCount":97},[],{"trials":3730,"activeCount":97},[3731],{"nctId":2340,"briefTitle":2341,"status":321,"phases":3732,"primaryCompletion":2343,"completion":2343,"start":2344,"enrollment":17,"conditions":3733,"interventions":3734},[86,87],[157,2346,2347,2348],[1936,2350,1938],{"trials":3736,"activeCount":97},[],{"trials":3738,"activeCount":97},[],{"trials":3740,"activeCount":97},[],{"intervention":3373,"totalTrials":135,"cells":3742},{"EARLY_PHASE1":3743,"PHASE1":3745,"PHASE2":3747,"PHASE3":3753,"PHASE4":3755,"NA":3757},{"trials":3744,"activeCount":97},[],{"trials":3746,"activeCount":97},[],{"trials":3748,"activeCount":97},[3749],{"nctId":3365,"briefTitle":3366,"status":103,"phases":3750,"primaryCompletion":3368,"completion":3368,"start":3369,"enrollment":1839,"conditions":3751,"interventions":3752},[87],[3371],[3337,3373,3374],{"trials":3754,"activeCount":97},[],{"trials":3756,"activeCount":97},[],{"trials":3758,"activeCount":97},[],{"intervention":3374,"totalTrials":135,"cells":3760},{"EARLY_PHASE1":3761,"PHASE1":3763,"PHASE2":3765,"PHASE3":3771,"PHASE4":3773,"NA":3775},{"trials":3762,"activeCount":97},[],{"trials":3764,"activeCount":97},[],{"trials":3766,"activeCount":97},[3767],{"nctId":3365,"briefTitle":3366,"status":103,"phases":3768,"primaryCompletion":3368,"completion":3368,"start":3369,"enrollment":1839,"conditions":3769,"interventions":3770},[87],[3371],[3337,3373,3374],{"trials":3772,"activeCount":97},[],{"trials":3774,"activeCount":97},[],{"trials":3776,"activeCount":97},[],{"intervention":3778,"totalTrials":135,"cells":3779},"AK104 IV infusion；Chiauranib",{"EARLY_PHASE1":3780,"PHASE1":3782,"PHASE2":3784,"PHASE3":3796,"PHASE4":3798,"NA":3800},{"trials":3781,"activeCount":97},[],{"trials":3783,"activeCount":97},[],{"trials":3785,"activeCount":97},[3786],{"nctId":3787,"briefTitle":3788,"status":103,"phases":3789,"primaryCompletion":3790,"completion":3791,"start":3792,"enrollment":2312,"conditions":3793,"interventions":3795},"NCT05505825","A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer",[86,87],"2024-07-19","2024-07-31","2022-08-26",[3794],"SCLC,Extensive Stage",[3778],{"trials":3797,"activeCount":97},[],{"trials":3799,"activeCount":97},[],{"trials":3801,"activeCount":97},[],{"intervention":636,"totalTrials":135,"cells":3803},{"EARLY_PHASE1":3804,"PHASE1":3806,"PHASE2":3808,"PHASE3":3814,"PHASE4":3816,"NA":3818},{"trials":3805,"activeCount":97},[],{"trials":3807,"activeCount":97},[],{"trials":3809,"activeCount":97},[3810],{"nctId":627,"briefTitle":628,"status":103,"phases":3811,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":3812,"interventions":3813},[87],[634],[47,419,220,636],{"trials":3815,"activeCount":97},[],{"trials":3817,"activeCount":97},[],{"trials":3819,"activeCount":97},[],{"intervention":3821,"totalTrials":135,"cells":3822},"AK104+anlotinib",{"EARLY_PHASE1":3823,"PHASE1":3825,"PHASE2":3827,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3824,"activeCount":97},[],{"trials":3826,"activeCount":97},[],{"trials":3828,"activeCount":97},[3829],{"nctId":3830,"briefTitle":3831,"status":103,"phases":3832,"primaryCompletion":3833,"completion":3834,"start":3835,"enrollment":3836,"conditions":3837,"interventions":3838},"NCT04646330","A Trial of AK104 Plus Anlotinib in NSCLC",[86,87],"2023-10-26","2025-07-30","2020-11-18",114,[328],[3821,3821,3821],{"trials":3840,"activeCount":97},[],{"trials":3842,"activeCount":97},[],{"trials":3844,"activeCount":97},[],{"intervention":3384,"totalTrials":135,"cells":3846},{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3851,"PHASE3":3857,"PHASE4":3859,"NA":3861},{"trials":3848,"activeCount":97},[],{"trials":3850,"activeCount":97},[],{"trials":3852,"activeCount":97},[3853],{"nctId":3376,"briefTitle":3377,"status":103,"phases":3854,"primaryCompletion":1100,"completion":1100,"start":3379,"enrollment":3380,"conditions":3855,"interventions":3856},[87],[3382],[3337,3384,3363],{"trials":3858,"activeCount":97},[],{"trials":3860,"activeCount":97},[],{"trials":3862,"activeCount":97},[],{"intervention":682,"totalTrials":135,"cells":3864},{"EARLY_PHASE1":3865,"PHASE1":3867,"PHASE2":3869,"PHASE3":3875,"PHASE4":3877,"NA":3879},{"trials":3866,"activeCount":97},[],{"trials":3868,"activeCount":97},[],{"trials":3870,"activeCount":97},[3871],{"nctId":674,"briefTitle":675,"status":103,"phases":3872,"primaryCompletion":677,"completion":678,"start":679,"enrollment":446,"conditions":3873,"interventions":3874},[87],[16],[682,47],{"trials":3876,"activeCount":97},[],{"trials":3878,"activeCount":97},[],{"trials":3880,"activeCount":97},[],{"intervention":3882,"totalTrials":135,"cells":3883},"AK120 or placebo- Part 1- Cohort 1",{"EARLY_PHASE1":3884,"PHASE1":3886,"PHASE2":3904,"PHASE3":3906,"PHASE4":3908,"NA":3910},{"trials":3885,"activeCount":97},[],{"trials":3887,"activeCount":97},[3888],{"nctId":3889,"briefTitle":3890,"status":103,"phases":3891,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":107,"conditions":3894,"interventions":3895},"NCT04256174","A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis",[86],"2021-10-29","2020-06-15",[19],[3882,3896,3897,3898,3899,3900,3901,3902,3903],"AK120 or placebo- Part 1- Cohort 2","AK120 or placebo- Part 1- Cohort 3","AK120 or placebo- Part 1- Cohort 4","AK120 or placebo- Part 1- Cohort 5","AK120 or placebo- Part 2- Cohort 1","AK120 or placebo- Part 2- Cohort 2","AK120 or placebo- Part 2- Cohort 3","AK120 or placebo- Part 2- Cohort 4",{"trials":3905,"activeCount":97},[],{"trials":3907,"activeCount":97},[],{"trials":3909,"activeCount":97},[],{"trials":3911,"activeCount":97},[],{"intervention":3896,"totalTrials":135,"cells":3913},{"EARLY_PHASE1":3914,"PHASE1":3916,"PHASE2":3922,"PHASE3":3924,"PHASE4":3926,"NA":3928},{"trials":3915,"activeCount":97},[],{"trials":3917,"activeCount":97},[3918],{"nctId":3889,"briefTitle":3890,"status":103,"phases":3919,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":107,"conditions":3920,"interventions":3921},[86],[19],[3882,3896,3897,3898,3899,3900,3901,3902,3903],{"trials":3923,"activeCount":97},[],{"trials":3925,"activeCount":97},[],{"trials":3927,"activeCount":97},[],{"trials":3929,"activeCount":97},[],{"intervention":3897,"totalTrials":135,"cells":3931},{"EARLY_PHASE1":3932,"PHASE1":3934,"PHASE2":3940,"PHASE3":3942,"PHASE4":3944,"NA":3946},{"trials":3933,"activeCount":97},[],{"trials":3935,"activeCount":97},[3936],{"nctId":3889,"briefTitle":3890,"status":103,"phases":3937,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":107,"conditions":3938,"interventions":3939},[86],[19],[3882,3896,3897,3898,3899,3900,3901,3902,3903],{"trials":3941,"activeCount":97},[],{"trials":3943,"activeCount":97},[],{"trials":3945,"activeCount":97},[],{"trials":3947,"activeCount":97},[],{"intervention":3898,"totalTrials":135,"cells":3949},{"EARLY_PHASE1":3950,"PHASE1":3952,"PHASE2":3958,"PHASE3":3960,"PHASE4":3962,"NA":3964},{"trials":3951,"activeCount":97},[],{"trials":3953,"activeCount":97},[3954],{"nctId":3889,"briefTitle":3890,"status":103,"phases":3955,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":107,"conditions":3956,"interventions":3957},[86],[19],[3882,3896,3897,3898,3899,3900,3901,3902,3903],{"trials":3959,"activeCount":97},[],{"trials":3961,"activeCount":97},[],{"trials":3963,"activeCount":97},[],{"trials":3965,"activeCount":97},[],{"intervention":3899,"totalTrials":135,"cells":3967},{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3976,"PHASE3":3978,"PHASE4":3980,"NA":3982},{"trials":3969,"activeCount":97},[],{"trials":3971,"activeCount":97},[3972],{"nctId":3889,"briefTitle":3890,"status":103,"phases":3973,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":107,"conditions":3974,"interventions":3975},[86],[19],[3882,3896,3897,3898,3899,3900,3901,3902,3903],{"trials":3977,"activeCount":97},[],{"trials":3979,"activeCount":97},[],{"trials":3981,"activeCount":97},[],{"trials":3983,"activeCount":97},[],{"intervention":3900,"totalTrials":135,"cells":3985},{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3994,"PHASE3":3996,"PHASE4":3998,"NA":4000},{"trials":3987,"activeCount":97},[],{"trials":3989,"activeCount":97},[3990],{"nctId":3889,"briefTitle":3890,"status":103,"phases":3991,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":107,"conditions":3992,"interventions":3993},[86],[19],[3882,3896,3897,3898,3899,3900,3901,3902,3903],{"trials":3995,"activeCount":97},[],{"trials":3997,"activeCount":97},[],{"trials":3999,"activeCount":97},[],{"trials":4001,"activeCount":97},[],{"intervention":3901,"totalTrials":135,"cells":4003},{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4012,"PHASE3":4014,"PHASE4":4016,"NA":4018},{"trials":4005,"activeCount":97},[],{"trials":4007,"activeCount":97},[4008],{"nctId":3889,"briefTitle":3890,"status":103,"phases":4009,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":107,"conditions":4010,"interventions":4011},[86],[19],[3882,3896,3897,3898,3899,3900,3901,3902,3903],{"trials":4013,"activeCount":97},[],{"trials":4015,"activeCount":97},[],{"trials":4017,"activeCount":97},[],{"trials":4019,"activeCount":97},[],{"intervention":3902,"totalTrials":135,"cells":4021},{"EARLY_PHASE1":4022,"PHASE1":4024,"PHASE2":4030,"PHASE3":4032,"PHASE4":4034,"NA":4036},{"trials":4023,"activeCount":97},[],{"trials":4025,"activeCount":97},[4026],{"nctId":3889,"briefTitle":3890,"status":103,"phases":4027,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":107,"conditions":4028,"interventions":4029},[86],[19],[3882,3896,3897,3898,3899,3900,3901,3902,3903],{"trials":4031,"activeCount":97},[],{"trials":4033,"activeCount":97},[],{"trials":4035,"activeCount":97},[],{"trials":4037,"activeCount":97},[],{"intervention":3903,"totalTrials":135,"cells":4039},{"EARLY_PHASE1":4040,"PHASE1":4042,"PHASE2":4048,"PHASE3":4050,"PHASE4":4052,"NA":4054},{"trials":4041,"activeCount":97},[],{"trials":4043,"activeCount":97},[4044],{"nctId":3889,"briefTitle":3890,"status":103,"phases":4045,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":107,"conditions":4046,"interventions":4047},[86],[19],[3882,3896,3897,3898,3899,3900,3901,3902,3903],{"trials":4049,"activeCount":97},[],{"trials":4051,"activeCount":97},[],{"trials":4053,"activeCount":97},[],{"trials":4055,"activeCount":97},[],{"intervention":4057,"totalTrials":135,"cells":4058},"AK115",{"EARLY_PHASE1":4059,"PHASE1":4061,"PHASE2":4073,"PHASE3":4075,"PHASE4":4077,"NA":4079},{"trials":4060,"activeCount":97},[],{"trials":4062,"activeCount":97},[4063],{"nctId":4064,"briefTitle":4065,"status":103,"phases":4066,"primaryCompletion":4067,"completion":4067,"start":4068,"enrollment":4069,"conditions":4070,"interventions":4072},"NCT05286970","A Clinical Study of AK115 in Healthy Subjects",[86],"2022-09-28","2022-03-18",42,[4071],"Healthy Volunteers",[4057],{"trials":4074,"activeCount":97},[],{"trials":4076,"activeCount":97},[],{"trials":4078,"activeCount":97},[],{"trials":4080,"activeCount":97},[],{"intervention":4082,"totalTrials":135,"cells":4083},"AK-104",{"EARLY_PHASE1":4084,"PHASE1":4086,"PHASE2":4098,"PHASE3":4100,"PHASE4":4102,"NA":4104},{"trials":4085,"activeCount":97},[],{"trials":4087,"activeCount":97},[4088],{"nctId":4089,"briefTitle":4090,"status":103,"phases":4091,"primaryCompletion":721,"completion":4092,"start":4093,"enrollment":4094,"conditions":4095,"interventions":4097},"NCT03261011","Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors",[86],"2023-04-13","2017-10-03",119,[4096],"Advanced Cancer",[4082],{"trials":4099,"activeCount":97},[],{"trials":4101,"activeCount":97},[],{"trials":4103,"activeCount":97},[],{"trials":4105,"activeCount":97},[],{"intervention":1759,"totalTrials":135,"cells":4107},{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4116,"PHASE3":4118,"PHASE4":4120,"NA":4122},{"trials":4109,"activeCount":97},[],{"trials":4111,"activeCount":97},[4112],{"nctId":1751,"briefTitle":1752,"status":103,"phases":4113,"primaryCompletion":1754,"completion":1754,"start":1755,"enrollment":1756,"conditions":4114,"interventions":4115},[86],[109],[206,1759],{"trials":4117,"activeCount":97},[],{"trials":4119,"activeCount":97},[],{"trials":4121,"activeCount":97},[],{"trials":4123,"activeCount":97},[],{"intervention":4125,"totalTrials":135,"cells":4126},"AK-105",{"EARLY_PHASE1":4127,"PHASE1":4129,"PHASE2":4141,"PHASE3":4143,"PHASE4":4145,"NA":4147},{"trials":4128,"activeCount":97},[],{"trials":4130,"activeCount":97},[4131],{"nctId":4132,"briefTitle":4133,"status":103,"phases":4134,"primaryCompletion":4135,"completion":4136,"start":4137,"enrollment":4138,"conditions":4139,"interventions":4140},"NCT03352531","Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors",[86],"2020-11-30","2023-10-28","2018-01-02",99,[4096],[4125],{"trials":4142,"activeCount":97},[],{"trials":4144,"activeCount":97},[],{"trials":4146,"activeCount":97},[],{"trials":4148,"activeCount":97},[],{"intervention":4150,"totalTrials":135,"cells":4151},"AK114",{"EARLY_PHASE1":4152,"PHASE1":4154,"PHASE2":4166,"PHASE3":4168,"PHASE4":4170,"NA":4172},{"trials":4153,"activeCount":97},[],{"trials":4155,"activeCount":97},[4156],{"nctId":4157,"briefTitle":4158,"status":640,"phases":4159,"primaryCompletion":4160,"completion":4160,"start":4161,"enrollment":501,"conditions":4162,"interventions":4165},"NCT05200273","A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114",[86],"2023-12-30","2022-03-15",[472,4163,4164],"Malignancy","Metastasis",[4150],{"trials":4167,"activeCount":97},[],{"trials":4169,"activeCount":97},[],{"trials":4171,"activeCount":97},[],{"trials":4173,"activeCount":97},[],{"intervention":4175,"totalTrials":135,"cells":4176},"AK101 IV",{"EARLY_PHASE1":4177,"PHASE1":4179,"PHASE2":4193,"PHASE3":4195,"PHASE4":4197,"NA":4199},{"trials":4178,"activeCount":97},[],{"trials":4180,"activeCount":97},[4181],{"nctId":4182,"briefTitle":4183,"status":103,"phases":4184,"primaryCompletion":4185,"completion":4186,"start":4187,"enrollment":10,"conditions":4188,"interventions":4190},"NCT06281704","A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis",[86],"2022-05-17","2022-12-31","2020-11-26",[4189],"Ulcerative Colitis",[4175,4191,4192],"AK101 SC","AK101 IV\u002FAK101 SC",{"trials":4194,"activeCount":97},[],{"trials":4196,"activeCount":97},[],{"trials":4198,"activeCount":97},[],{"trials":4200,"activeCount":97},[],{"intervention":4191,"totalTrials":135,"cells":4202},{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4211,"PHASE3":4213,"PHASE4":4215,"NA":4217},{"trials":4204,"activeCount":97},[],{"trials":4206,"activeCount":97},[4207],{"nctId":4182,"briefTitle":4183,"status":103,"phases":4208,"primaryCompletion":4185,"completion":4186,"start":4187,"enrollment":10,"conditions":4209,"interventions":4210},[86],[4189],[4175,4191,4192],{"trials":4212,"activeCount":97},[],{"trials":4214,"activeCount":97},[],{"trials":4216,"activeCount":97},[],{"trials":4218,"activeCount":97},[],{"intervention":4192,"totalTrials":135,"cells":4220},{"EARLY_PHASE1":4221,"PHASE1":4223,"PHASE2":4229,"PHASE3":4231,"PHASE4":4233,"NA":4235},{"trials":4222,"activeCount":97},[],{"trials":4224,"activeCount":97},[4225],{"nctId":4182,"briefTitle":4183,"status":103,"phases":4226,"primaryCompletion":4185,"completion":4186,"start":4187,"enrollment":10,"conditions":4227,"interventions":4228},[86],[4189],[4175,4191,4192],{"trials":4230,"activeCount":97},[],{"trials":4232,"activeCount":97},[],{"trials":4234,"activeCount":97},[],{"trials":4236,"activeCount":97},[],{"intervention":4238,"totalTrials":135,"cells":4239},"AK111 or Placebo",{"EARLY_PHASE1":4240,"PHASE1":4242,"PHASE2":4252,"PHASE3":4254,"PHASE4":4256,"NA":4258},{"trials":4241,"activeCount":97},[],{"trials":4243,"activeCount":97},[4244],{"nctId":4245,"briefTitle":4246,"status":103,"phases":4247,"primaryCompletion":4248,"completion":4248,"start":4249,"enrollment":555,"conditions":4250,"interventions":4251},"NCT03622021","A Study of AK111 in Healthy Subjects",[86],"2019-09-09","2018-08-14",[27],[4238],{"trials":4253,"activeCount":97},[],{"trials":4255,"activeCount":97},[],{"trials":4257,"activeCount":97},[],{"trials":4259,"activeCount":97},[]]